://disabled.local/en/www-amgen-com/media/news-releases/2017/12/amgen-teams-up-with-cambridge-biotech-community-to-select-two-startups-to-receive-golden-tickets-at-labcentral/2017-12-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/12/amgen-announces-15-percent-increase-in-2018-first-quarter-dividend/2017-12-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/12/kyprolis-carfilzomib-extended-overall-survival-in-patients-with-relapsed-or-refractory-multiple-myeloma-in-phase-3-aspire-trial/2017-12-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/12/amgen-foundation-pledges-up-to-500000-in-relief-to-victims-of-the-southern-california-wildfires/2017-12-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/12/new-data-to-be-presented-at-ash-2017-underscore-amgens-commitment-to-improving-lives-and-changing-outcomes-for-patients-with-difficulttotreat-blood-cancers/2017-12-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/12/amgen-to-webcast-investor-call-at-ash-2017/2017-12-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/12/fda-approves-amgens-repatha-evolocumab-to-prevent-heart-attack-and-stroke/2017-12-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/11/aimovig-erenumab-phase-3-strive-data-published-in-the-new-england-journal-of-medicine-demonstrate-significant-sustained-efficacy-in-migraine-prevention/2017-11-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/11/amgen-to-present-at-the-evercore-isi-2017-biopharma-catalystdeep-dive-conference/2017-11-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/11/amgen-launches-the-enbrel-mini-single-dose-prefilled-cartridge-with-autotouch-reusable-autoinjector-that-is-ergonomically-designed-for-patients/2017-11-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/11/new-analyses-presented-at-aha-2017-show-repatha-evolocumab-significantly-reduced-cardiovascular-events-in-patients-with-peripheral-artery-disease-and-in-patients-with-a-history-of-heart-attacks/2017-11-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/11/amgen-and-allergan-receive-positive-chmp-opinion-for-abp-215-biosimilar-bevacizumab-for-the-treatment-of-certain-types-of-cancer/2017-11-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/11/amgen-announces-new-analyses-of-highrisk-patient-subgroups-from-repatha-evolocumab-cardiovascular-outcomes-study-at-aha-scientific-sessions-2017/2017-11-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/11/amgen-and-novartis-announce-expanded-collaboration-with-banner-alzheimers-institute-in-pioneering-prevention-program/2017-11-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/10/amgen-reports-third-quarter-2017-financial-results/2017-10-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/10/amgen-announces-appointment-of-wanda-m--austin-to-board-of-directors/2017-10-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/10/amgen-announces-2017-fourth-quarter-dividend/2017-10-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/10/awardwinning-journalist-and-cancer-survivor-joan-lunden-partners-with-amgen-to-launch-at-home-with-joan-to-empower-patients-battling-cancer/2017-10-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/10/phase-3-arrow-study-of-onceweekly-kyprolis-carfilzomib-regimen-meets-primary-endpoint-of-progressionfree-survival-in-relapsed-and-refractory-multiple-myeloma-patients/2017-10-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/10/amgen-announces-webcast-of-2017-third-quarter-financial-results/2017-10-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/10/amgen-and-boston-childrens-hospital-enter-a-collaboration-to-find-new-genes-and-drug-targets-for-severe-pain-syndromes/2017-10-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/10/amgen-foundation-awards-khan-academy-$3-million-to-support-development-of-free-comprehensive-biology-lessons/2017-10-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/10/fda-accepts-supplemental-biologics-license-application-for-prolia-denosumab-in-glucocorticoidinduced-osteoporosis/2017-10-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/10/amgen-and-labcentral-open-nomination-process-for-lab-residency/2017-10-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/10/first-randomized-study-to-evaluate-imlygic-talimogene-laherparepvec-an-oncolytic-viral-therapy-in-combination-with-a-checkpoint-inhibitor-published-in-the-journal-of-clinical-oncology/2017-10-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/10/amgen-and-cytomx-therapeutics-announce-strategic-collaboration-in-immuno-oncology/2017-10-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/09/amgen-and-abbvie-agree-to-settlement-allowing-commercialization-of-amgevita/2017-09-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/09/amgen-and-simcere-announce-strategic-collaboration-to-co-develop-and-commercialize-biosimilars-in-china/2017-09-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/09/amgen-provides-update-on-hurricane-maria/2017-09-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/09/amgen-foundation-pledges-up-to-$5-million-to-hurricane-maria-relief-efforts/2017-09-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/09/new-fourier-analysis-shows-repatha-evolocumab-reduces-cardiovascular-events-in-patients-with-diabetes/2017-09-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/09/fda-approves-amgen-and-allergans-mvasi-bevacizumabawwb-for-the-treatment-of-five-types-of-cancer/2017-09-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference/2017-09-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/09/evenity-romosozumab-arch-study-results-published-in-the-new-england-journal-of-medicine/2017-09-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/09/amgen-and-allergan-present-phase-3-data-on-biosimilar-trastuzumab-candidate-abp-980-at-the-european-society-for-medical-oncology-2017-congress/2017-09-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/09/amgen-highlights-the-latest-evenity-romosozumab-and-prolia-denosumab-research-at-the-american-society-for-bone-and-mineral-research-annual-meeting/2017-09-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/09/new-data-demonstrate-aimovig-erenumab-reduced-monthly-migraine-days-in-patients-who-failed-previous-preventive-therapies/2017-09-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference/2017-09-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/09/tezepelumab-significantly-reduced-asthma-exacerbations-for-a-broad-population-of-patients-with-severe-uncontrolled-asthma/2017-09-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/08/european-commission-approves-expanded-use-of-mimpara-cinacalcet-for-the-treatment-of-secondary-hyperparathyroidism-in-children-with-endstage-renal-disease-on-dialysis/2017-08-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/08/longterm-analysis-of-phase-3-headtohead-study-confirms-kyprolis-carfilzomib-regimen-extends-overall-survival-in-patients-with-relapsed-multiple-myeloma/2017-08-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/08/fda-accepts-amgens-filing-of-a-supplemental-new-drug-application-to-add-overall-survival-results-to-kyprolis-carfilzomib-label/2017-08-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/08/new-virtual-histology-substudy-evaluates-impact-of-repatha-evolocumab-on-coronary-artery-plaque-composition/2017-08-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/08/new-analysis-shows-repatha-evolocumab-reduces-cardiovascular-events-in-patients-with-history-of-stroke/2017-08-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/08/new-repatha-evolocumab-analysis-demonstrates-cardiovascular-outcomes-efficacy-and-safety-of-achieving-very-low-ldlc-levels/2017-08-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/08/amgen-foundation-expands-the-amgen-biotech-experience-bringing-total-program-reach-to-900000-high-school-students-by-2020/2017-08-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/08/new-economic-analysis-based-on-repatha-evolocumab-outcomes-data-published-in-jama-cardiology/2017-08-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/08/amgen-to-present-new-data-from-the-repatha-evolocumab-cardiovascular-outcomes-study-at-esc-congress-2017/2017-08-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/08/amgen-and-humana-partner-for-improved-health-outcomes-and-efficiency/2017-08-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/08/repatha-evolocumab-phase-3-cognitive-function-study-results-published-in-the-new-england-journal-of-medicine/2017-08-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/07/amgen-and-allergan-submit-biosimilar-biologics-license-application-for-abp-980-to-us-food-and-drug-administration/2017-07-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/07/amgen-announces-2017-third-quarter-dividend/2017-07-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/07/fda-grants-priority-review-for-amgens-supplemental-biologics-license-application-for-repatha-evolocumab-to-include-data-on-reducing-risk-of-cardiovascular-events/2017-07-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/07/amgen-reports-second-quarter-2017-financial-results/2017-07-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/07/amgen-announces-webcast-of-2017-second-quarter-financial-results/2017-07-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/07/amgen-and-ucb-provide-update-on-regulatory-status-of-evenity-romosozumab-in-the-us/2017-07-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/07/amgen-submits-regulatory-applications-in-us-and-europe-to-include-overall-survival-data-in-kyprolis-carfilzomib-label/2017-07-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/07/amgen-and-allergan-to-discuss-data-supporting-biologics-license-application-for-abp-215-a-biosimilar-candidate-to-avastin-bevacizumab/2017-07-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/07/second-phase-3-study-shows-kyprolis-carfilzomib-regimen-significantly-improves-overall-survival-in-patients-with-relapsed-multiple-myeloma/2017-07-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/07/amgen-and-qb3953-announce-winners-of-the-amgen-golden-ticket/2017-07-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/06/fda-approves-vectibix-panitumumab-for-use-in-wildtype-ras-metastatic-colorectal-cancer/2017-06-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/06/amgen-receives-positive-chmp-opinion-to-expand-use-of-mimpara-cinacalcet-for-the-treatment-of-secondary-hyperparathyroidism-in-certain-children-with-endstage-renal-disease-on-dialysis/2017-06-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/06/amgen-to-present-new-data-at-22nd-congress-of-the-european-hematology-association/2017-06-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/06/fda-accepts-amgens-supplemental-biologics-license-application-to-expand-indication-for-xgeva-denosumab-to-include-multiple-myeloma-patients/2017-06-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/06/amgen-to-present-at-the-goldman-sachs-38th-annual-global-healthcare-conference/2017-06-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/06/amgen-and-allergan-announce-fda-advisory-committee-meeting-to-review-abp-215-a-biosimilar-candidate-to-bevacizumab/2017-06-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/06/amgen-submits-regulatory-applications-for-repatha-evolocumab-cardiovascular-outcomes-data-in-us-and-europe/2017-06-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/06/amgen-presents-new-data-from-phase-3-xgeva-denosumab-study-in-patients-with-multiple-myeloma-at-asco-2017/2017-06-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/06/amgen-showcases-a-legacy-of-science-innovation-and-collaboration-in-cambridge/2017-06-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/05/amgen-and-ucb-announce-topline-phase-3-data-from-activecomparator-study-of-evenity-romosozumab-in-postmenopausal-women-with-osteoporosis/2017-05-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/05/repatha-evolocumab-reduced-cardiovascular-events-in-patients-with-baseline-ldlc-levels-below-current-targets/2017-05-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders/2017-05-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/05/amgen-highlights-data-to-be-presented-at-asco-2017-across-oncology-portfolio/2017-05-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/05/amgen-to-present-at-the-bank-of-america-merrill-lynch-2017-health-care-conference/2017-05-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/05/amgen-and-harvard-pilgrim-agree-to-first-cardiovascular-outcomesbased-refund-contract-for-repatha-evolocumab/2017-05-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/04/amgen-to-participate-in-the-2017-world-medical-innovation-forum-focused-on-cardiovascular-disease/2017-04-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/04/amgen-reports-first-quarter-2017-financial-results/2017-04-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/04/amgen-announces-expanded-commercial-collaboration-with-novartis-for-erenumab-in-migraine/2017-04-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/04/amgen-announces-webcast-of-2017-first-quarter-financial-results/2017-04-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/04/amgen-launches-neulasta-pegfilgrastim-onpro-narratives/2017-04-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/04/amgen-submits-applications-in-the-us-and-europe-to-expand-current-indication-for-xgeva-denosumab-to-include-patients-with-multiple-myeloma/2017-04-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/04/amgen-and-ucb-report-new-data-at-endo-2017-examining-the-option-of-a-second-course-of-treatment-with-evenity-romosozumab/2017-04-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/03/amgen-to-highlight-new-preclinical-data-at-the-american-association-for-cancer-research-aacr-annual-meeting/2017-03-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/03/amgen-awards-three-golden-tickets-for-labcentral-residency/2017-03-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/03/european-commission-approves-amgevita-biosimilar-adalimumab-for-the-treatment-of-certain-inflammatory-diseases/2017-03-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/03/analyses-of-pcsk9-inhibitor-prescription-rejection-rates-demonstrate-significant-access-barriers-for-appropriate-patients/2017-03-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/03/lowering-ldl-levels-with-repatha-evolocumab-did-not-adversely-affect-cognitive-function-in-landmark-phase-3-study/2017-03-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/03/amgen-to-webcast-investor-meeting-at-upcoming-american-college-of-cardiology-scientific-sessions/2017-03-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/03/repatha-evolocumab-demonstrates-reduced-need-for-apheresis-in-patients-with-high-ldl-cholesterol-in-phase-3-study/2017-03-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/03/amgen-announces-2017-second-quarter-dividend/2017-03-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/03/amgen-presents-new-data-from-phase-3-xgeva-denosumab-study-in-multiple-myeloma-patients-at-the-16th-international-myeloma-workshop/2017-03-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/03/amgen-presents-overall-survival-data-from-kyprolis-carfilzomib-phase-3-endeavor-trial-at-16th-international-myeloma-workshop/2017-03-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/03/amgen-to-present-at-the-cowen-and-company-37th-annual-health-care-conference/2017-03-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/02/amgen-submits-supplemental-biologics-license-application-for-blincyto-blinatumomab-in-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukemia/2017-02-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/02/fda-approves-amgens-parsabiv-etelcalcetide-first-new-treatment-in-more-than-a-decade-for-secondary-hyperparathyroidism-in-adult-patients-on-hemodialysis/2017-02-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/02/amgen-reports-fourth-quarter-and-full-year-2016-financial-results/2017-02-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/01/amgen-receives-positive-chmp-opinion-for-abp-501-biosimilar-adalimumab-for-the-treatment-of-certain-inflammatory-diseases/2017-01-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/01/study-results-published-in-the-journal-of-the-american-medical-association-show-amgens-parsabiv-etelcalcetide-significantly-reduced-serum-parathyroid-hormone-in-adults-with-secondary-hyperparathyroidism-on-hemodialysis/2017-01-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/01/amgen-statement-on-january-9-2017-us-district-court-decision/2017-01-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/01/amgen-and-davita-enter-into-new-sourcing-and-supply-agreement/2017-01-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/01/amgen-and-immatics-enter-strategic-collaboration-to-develop-novel-bispecific-cancer-immunotherapies/2017-01-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/01/court-grants-permanent-injunction-for-infringement-of-amgens-repatha-patents/2017-01-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2017/01/amgen-to-present-at-the-35th-annual-j-p--morgan-healthcare-conference/2017-01-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/12/amgen-announces-15-percent-increase-in-2017-first-quarter-dividend/2016-12-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/12/amgen-and-ucb-announce-submission-of-application-for-investigational-osteoporosis-medication-romosozumab-in-japan/2016-12-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/12/new-repatha-evolocumab-dose-delivery-option-receives-positive-chmp-opinion/2016-12-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/12/amgen-announces-launch-of-blood-counts-and-collaboration-with-storycorps-to-record-and-share-stories-of-those-impacted-by-multiple-myeloma/2016-12-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/12/amgen-and-allergan-submit-biosimilar-marketing-authorization-application-to-european-medicines-agency-for-abp-215-a-biosimilar-candidate-to-bevacizumab/2016-12-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/12/amgen-to-present-at-the-citi-2016-global-healthcare-conference/2016-12-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/11/the-lancet-publishes-results-from-cosmic-hf-trial-showing-omecamtiv-mecarbil-significantly-improved-cardiac-function-in-patients-with-chronic-heart-failure/2016-11-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/11/amgen-announces-presentation-of-new-data-in-acute-lymphoblastic-leukemia-multiple-myeloma-and-immune-thrombocytopenia-at-ash-2016/2016-11-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/11/amgen-announces-erenumab-significantly-reduces-monthly-migraine-days-in-patients-with-episodic-migraine-in-second-phase-3-study/2016-11-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/11/amgen-and-allergan-submit-biosimilar-biologics-license-application-for-abp-215-to-u-s--food-and-drug-administration/2016-11-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/11/repatha-evolocumab-regresses-atherosclerosis-in-patients-with-coronary-artery-disease/2016-11-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/11/new-ten-to-watch-list-highlights-top-amgen-scholars-poised-to-impact-the-future-of-science-and-medicine/2016-11-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/11/results-from-phase-3-bridge-study-show-romosozumab-significantly-increases-bone-mineral-density-in-men-with-osteoporosis/2016-11-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/11/european-commission-approves-parsabiv-etelcalcetide-for-the-treatment-of-secondary-hyperparathyroidism-in-adults-on-hemodialysis/2016-11-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/11/amgen-to-webcast-investor-meeting-at-upcoming-american-heart-association-scientific-sessions-2016/2016-11-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/11/amgen-announces-collaboration-with-janssen-to-cofund-studies-with-kyprolis-carfilzomib-and-darzalex-daratumumab-in-patients-with-multiple-myeloma/2016-11-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/11/data-to-be-presented-at-acrarhp-2016-annual-meeting-show-amgens-ongoing-commitment-to-therapies-for-patients-with-serious-inflammatory-and-bone-diseases/2016-11-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/11/fda-approves-expanded-use-of-enbrel-etanercept-to-treat-children-with-chronic-moderatetosevere-plaque-psoriasis/2016-11-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/11/amgen-to-present-at-the-credit-suisse-25th-annual-healthcare-conference/2016-11-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/11/amgen-appoints-lori-johnston-as-senior-vice-president-human-resources/2016-11-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/10/amgen-highlights-repatha-evolocumab-glagov-imaging-study-amongst-data-to-be-presented-at-aha-scientific-sessions-2016/2016-10-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/10/amgen-reports-third-quarter-2016-financial-results/2016-10-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/10/amgen-to-invest-in-israel-based-ehealth-ventures/2016-10-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/10/amgen-announces-webcast-of-2016-third-quarter-financial-results/2016-10-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/10/amgen-announces-positive-topline-results-from-xgeva-denosumab-phase-3-trial-for-delay-of-bone-complications-in-multiple-myeloma-patients/2016-10-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/10/amgen-announces-2016-fourth-quarter-dividend/2016-10-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/10/amgen-announces-appointment-of-ellen-j--kullman-to-board-of-directors/2016-10-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/10/new-retrospective-analyses-confirm-vectibix-panitumumab-treatment-provided-survival-benefit-over-chemotherapy-with-or-without-bevacizumab-in-metastatic-colorectal-cancer-patients-with-tumors-of-leftsided-origin/2016-10-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/10/new-amgen-data-in-melanoma-and-metastatic-colorectal-cancer-to-be-presented-at-the-european-society-for-medical-oncology-2016-congress/2016-10-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/10/amgen-to-participate-in-citi-biotech-rd-conference-call/2016-10-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/10/study-results-published-in-journal-of-clinical-oncology-show-blincyto-blinatumomab-induced-complete-remission-in-heavily-pretreated-pediatric-patients-with-philadelphia-chromosomenegative-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukemia/2016-10-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/amgen-and-arrowhead-pharmaceuticals-announce-two-cardiovascular-collaborations/2016-09-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/amgen-announces-erenumab-significantly-reduces-monthly-migraine-days-in-patients-with-episodic-migraine-in-first-phase-3-study/2016-09-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/amgen-announces-topline-results-from-phase-3-kyprolis-carfilzomib-clarion-study-in-newly-diagnosed-multiple-myeloma-patients/2016-09-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/amgen-opens-nomination-process-for-labcentral-residency/2016-09-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/amgen-and-ucb-announce-u-s--fda-acceptance-of-biologics-license-application-for-romosozumab/2016-09-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/fda-approves-amgens-amjevita-adalimumabatto-for-treatment-of-seven-inflammatory-diseases/2016-09-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/amgen-announces-positive-topline-results-from-phase-3-glagov-imaging-study-of-repatha-evolocumab/2016-09-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/results-from-phase-3-frame-study-of-romosozumab-showed-significant-reductions-in-both-new-vertebral-and-clinical-fractures-in-postmenopausal-women-with-osteoporosis/2016-09-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/amgen-receives-positive-chmp-opinion-for-parsabiv-etelcalcetide-for-the-treatment-of-secondary-hyperparathyroidism-in-adult-patients-with-chronic-kidney-disease-on-hemodialysis/2016-09-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/amgen-presents-positive-data-at-ehmtic-2016-demonstrating-erenumab-significantly-reduces-monthly-migraine-days-in-patients-with-chronic-migraine/2016-09-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/amgen-to-webcast-investor-call/2016-09-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference/2016-09-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference/2016-09-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/amgen-to-highlight-19-abstracts-on-osteoporosis-disease-state-and-treatment-at-american-society-for-bone-and-mineral-research-annual-meeting/2016-09-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/fda-approves-blincyto-blinatumomab-for-use-in-pediatric-patients-with-philadelphia-chromosomenegative-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukemia/2016-09-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/amgen-obtains-global-development-and-commercial-rights-from-boehringer-ingelheim-for-investigational-bite-immuno-oncology-drug-for-multiple-myeloma/2016-09-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/09/amgen-and-servier-extend-omecamtiv-mecarbil-collaboration-in-chronic-heart-failure/2016-09-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/08/amgen-announces-positive-topline-results-from-phase-3-study-of-prolia-denosumab-in-patients-receiving-glucocorticoid-therapy/2016-08-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/08/new-repatha-evolocumab-analyses-show-efficacy-and-safety-across-risk-groups-in-results-presented-at-esc-congress-2016/2016-08-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/08/amgen-provides-update-on-status-of-parsabiv-etelcalcetide-new-drug-application-nda-submitted-to-the-us-food-and-drug-administration-fda/2016-08-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/08/new-data-add-to-understanding-of-repatha-evolocumab-in-multiple-patient-populations/2016-08-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/08/amgen-and-advaxis-enter-global-cancer-immunotherapies-collaboration/2016-08-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/07/amgen-reports-second-quarter-2016-financial-results/2016-07-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/07/amgen-announces-webcast-of-2016-second-quarter-financial-results/2016-07-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/07/amgen-announces-2016-third-quarter-dividend/2016-07-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/07/amgen-and-ucb-submit-biologics-license-application-for-romosozumab-to-the-fda/2016-07-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/07/amgen-and-allergan-announce-top-line-results-from-phase-3-study-evaluating-abp-980-compared-with-trastuzumab-in-patients-with-human-epidermal-growth-factor-receptor-2-positive-early-breast-cancer/2016-07-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/07/amgen-announces-settlement-of-securities-litigation/2016-07-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/07/amgen-and-daiichi-sankyo-announce-agreement-to-commercialize-biosimilars-in-japan/2016-07-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/07/amgen-to-discuss-data-supporting-biologics-license-application-for-abp-501-a-biosimilar-candidate-to-adalimumab/2016-07-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/07/fda-approves-first-and-only-single-monthly-injection-for-a-pcsk9-inhibitor/2016-07-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/07/european-commission-approves-extended-indication-for-amgens-kyprolis-carfilzomib-for-the-treatment-of-relapsed-multiple-myeloma-patients/2016-07-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/06/amgen-sponsors-qb3953-incubator-for-life-science-startups/2016-06-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/06/amgen-appoints-esteban-santos-executive-vice-president-operations/2016-06-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/06/amgen-announces-fda-advisory-committee-meeting-to-review-abp-501-a-biosimilar-candidate-to-adalimumab/2016-06-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/06/new-analyses-from-pivotal-phase-3-studies-show-kyprolis-carfilzomib-allows-patients-with-relapsed-multiple-myeloma-to-live-longer-without-disease-progression/2016-06-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/06/amgen-announces-expiration-and-final-results-of-senior-notes-exchange-offers/2016-06-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/06/blincyto-blinatumomab-improved-overall-survival-in-patients-with-bcell-precursor-acute-lymphoblastic-leukemia/2016-06-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/06/amgen-announces-erenumab-amg-334-significantly-reduces-patients-monthly-migraine-days-in-phase-2-study-for-the-prevention-of-chronic-migraine/2016-06-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/06/new-national-survey-sheds-light-on-how-to-better-engage-students-in-science-education/2016-06-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/06/new-phase-3-secondary-analysis-shows-progressionfree-survival-benefit-in-early-relapsing-multiple-myeloma-patients-treated-with-kyprolis-carfilzomibbased-regimen/2016-06-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/06/amgen-announces-launch-of-kyprolis-carfilzomib-central-an-online-news-resource-demonstrating-the-impact-of-relapsed-multiple-myeloma-on-the-lives-of-patients-and-caregivers/2016-06-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/06/amgen-to-present-at-the-goldman-sachs-37th-annual-global-healthcare-conference/2016-06-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/05/amgen-receives-positive-chmp-opinion-to-extend-indication-of-kyprolis-carfilzomib-for-the-treatment-of-relapsed-multiple-myeloma/2016-05-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/05/kyprolis-carfilzomib-demonstrates-economic-value-in-relapsed-or-refractory-multiple-myeloma-manuscript-published-in-journal-of-medical-economics/2016-05-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/05/amgen-announces-early-tender-results-of-senior-notes-exchange-offers/2016-05-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/05/amgen-announces-pricing-terms-of-senior-notes-exchange-offers/2016-05-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders/2016-05-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/05/amgen-highlights-data-to-be-presented-at-21st-congress-of-the-european-hematology-association/2016-05-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/05/amgen-data-to-be-presented-at-asco-2016-demonstrates-more-insights-into-treatment-options-for-patients/2016-05-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/05/landmark-decode-genetics-study-points-to-a-new-mechanism-that-affects-cholesterol-levels-and-the-risk-of-heart-disease/2016-05-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/05/amgens-breakaway-from-cancer-public-service-announcement-delivers-message-that-education-resources-and-hope-are-essential-in-the-fight-against-cancer/2016-05-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/05/amgen-commences-exchange-offers-for-certain-series-of-outstanding-senior-notes-from-exchange-eligible-holders/2016-05-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/05/hall-of-fame-quarterback-joe-montana-and-amgen-team-up-to-launch-breakaway-from-heart-disease-to-make-heart-health-a-priority/2016-05-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/05/platelet-biogenesis-wins-amgen-golden-ticket-for-labcentral/2016-05-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/05/amgen-to-present-at-the-bank-of-america-merrill-lynch-2016-health-care-conference/2016-05-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/05/fda-grants-priority-review-for-amgens-supplemental-biologics-license-application-for-blincyto-blinatumomab/2016-05-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/04/amgens-first-quarter-2016-revenues-increased-10-percent-to-55-billion-and-adjusted-earnings-per-share-eps-increased-17-percent-to-290/2016-04-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/04/amgen-announces-webcast-of-2016-first-quarter-financial-results/2016-04-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/04/amgen-to-participate-in-the-2016-world-medical-innovation-forum-on-cancer/2016-04-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/04/nplate-romiplostim-study-in-the-lancet-shows-significant-increase-in-durable-platelet-response-among-children-with-immune-thrombocytopenia/2016-04-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/04/positive-efficacy-and-tolerability-study-of-repatha-evolocumab-in-statinintolerant-patients-published-in-journal-of-the-american-medical-association/2016-04-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/04/amgen-and-ucb-present-positive-data-at-endo-2016-comparing-romosozumab-with-teriparatide/2016-04-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/03/amgen-to-present-repatha-evolocumab-data-at-acc16/2016-03-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/03/amgen-and-ucb-announce-positive-top-line-results-from-phase-3-study-evaluating-romosozumab-in-men-with-osteoporosis/2016-03-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/03/amgen-wins-patent-case-on-repatha-evolocumab/2016-03-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/03/fda-accepts-amgens-supplemental-biologics-license-application-for-the-expanded-use-of-enbrel-etanercept-to-treat-pediatric-patients-with-chronic-severe-plaque-psoriasis/2016-03-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/03/amgen-to-present-at-the-cowen-and-company-36th-annual-health-care-conference/2016-03-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/03/amgen-announces-2016-second-quarter-dividend/2016-03-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/03/amgen-submits-supplemental-biologics-license-application-for-blincyto-blinatumomab/2016-03-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/02/amgen-and-ucb-announce-positive-top-line-results-from-the-phase-3-study-of-romosozumab-in-postmenopausal-women-with-osteoporosis/2016-02-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/02/phase-3-study-demonstrates-aranesp-darbepoetin-alfa-reduces-red-blood-cell-transfusions-in-patients-with-myelodysplastic-syndrome-mds/2016-02-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/02/amgen-to-present-at-the-leerink-partners-5th-annual-global-healthcare-conference/2016-02-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/02/phase-3-study-of-blincyto-blinatumomab-met-primary-endpoint-of-overall-survival-in-patients-with-bcell-precursor-acute-lymphoblastic-leukemia/2016-02-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/02/amgen-announces-positive-topline-results-from-phase-3-gauss3-trial-of-repatha-evolocumab-in-statinintolerant-patients-with-high-cholesterol/2016-02-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/01/amgens-2015-revenues-increased-8-percent-to-217-billion-and-adjusted-earnings-per-share-eps-increased-19-percent-to-1038/2016-01-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/01/fda-accepts-amgens-biosimilar-biologics-license-application-for-abp-501/2016-01-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/01/amgen-announces-webcast-of-2015-fourth-quarter-and-full-year-financial-results/2016-01-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/01/vectibix-panitumumab-and-best-supportive-care-improves-overall-survival-compared-to-best-supportive-care-in-chemorefractory-kras-and-ras-wildtype-metastatic-colorectal-cancer/2016-01-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/01/amgens-repatha-evolocumab-approved-as-first-pcsk9-inhibitor-in-japan-for-the-treatment-of-high-cholesterol/2016-01-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/01/fda-approves-new-kyprolis-carfilzomib-combination-therapy-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma/2016-01-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2016/01/amgen-to-present-at-the-34th-annual-j-p--morgan-healthcare-conference/2016-01-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/12/european-commission-approves-amgens-imlygic-talimogene-laherparepvec-as-first-oncolytic-immunotherapy-in-europe/2015-12-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/12/amgen-announces-27-percent-increase-in-2016-first-quarter-dividend/2015-12-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/12/amgen-reacquires-all-product-rights-to-prolia-denosumab-xgeva-denosumab-and-vectibix-panitumumab-from-gsk-in-48-countries/2015-12-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/12/amgen-presents-data-from-three-trials-evaluating-blincyto-blinatumomab-in-acute-lymphoblastic-leukemia-at-ash-2015/2015-12-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/12/new-analyses-presented-at-ash-2015-demonstrate-the-potential-of-kyprolis-carfilzomib-as-backbone-therapy-in-multiple-myeloma/2015-12-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/12/pivotal-headtohead-endeavor-study-results-published-in-the-lancet-oncology-demonstrate-superiority-of-kyprolis-carfilzomib-combination-over-velcade-bortezomib-combination/2015-12-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/12/amgen-submits-application-in-europe-to-expand-indication-of-kyprolis-carfilzomib-for-the-treatment-of-relapsed-multiple-myeloma/2015-12-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/12/amgen-and-merck-announce-cancer-immunotherapy-collaboration-for-patients-with-non-hodgkin-lymphoma/2015-12-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/12/amgens-first-biosimilar-marketing-authorization-application-submitted-to-european-medicines-agency-for-abp-501/2015-12-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/11/amgens-first-biosimilar-biologics-license-application-for-abp-501-submitted-to-us-food-and-drug-administration/2015-11-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/11/european-commission-approves-amgens-blincyto-blinatumomab-for-the-treatment-of-adults-with-philadelphia-chromosomenegative-relapsed-or-refractory-bprecursor-acute-lymphoblastic-leukemia/2015-11-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/11/amgen-announces-repatha-preferred-position-on-cvs-health-commercial-formularies/2015-11-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/11/european-commission-approves-kyprolis-carfilzomib-for-combination-use-in-the-treatment-of-patients-with-relapsed-multiple-myeloma/2015-11-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/11/amgen-to-present-imlygic-talimogene-laherparepvec-data-at-the-2015-international-congress-of-the-society-for-melanoma-research/2015-11-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/11/amgen-presents-detailed-results-from-phase-3-study-demonstrating-clinical-equivalence-of-biosimilar-candidate-abp-501-with-adalimumab/2015-11-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/11/amgen-and-cytokinetics-announce-late-breaking-presentation-of-cosmic-hf-trial-at-aha-scientific-sessions-2015/2015-11-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/11/amgen-presents-detailed-data-comparing-etelcalcetide-with-cinacalcet-in-patients-with-secondary-hyperparathyroidism-receiving-hemodialysis/2015-11-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/11/fda-accepts-amgens-new-drug-application-for-novel-intravenous-calcimimetic-etelcalcetide/2015-11-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/11/amgen-to-present-at-the-credit-suisse-24th-annual-healthcare-conference/2015-11-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/11/key-data-for-amgen-medicines-in-relapsed-multiple-myeloma-and-acute-lymphoblastic-leukemia-to-be-presented-at-ash-2015/2015-11-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/11/amgen-highlights-data-to-be-presented-at-2015-american-college-of-rheumatology-and-association-for-rheumatology-health-professionals-annual-meeting/2015-11-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/11/amgen-to-highlight-cardiovascular-portfolio-at-american-heart-association-scientific-sessions-2015/2015-11-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/10/amgens-third-quarter-2015-revenues-increased-14-percent-to-57-billion-and-adjusted-earnings-per-share-eps-increased-18-percent-to-272/2015-10-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/10/fda-approves-imlygic-talimogene-laherparepvec-as-first-oncolytic-viral-therapy-in-the-us/2015-10-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/10/amgen-and-cytokinetics-announce-positive-topline-results-from-cosmichf-a--phase-2-trial-of-omecamtiv-mecarbil-in-patients-with-chronic-heart-failure/2015-10-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/10/amgen-announces-webcast-of-2015-third-quarter-financial-results/2015-10-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/10/amgen-receives-chmp-positive-opinion-for-imlygic-talimogene-laherparepvec/2015-10-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/10/amgen-foundation-announces-new-$4-million-commitment-to-bring-hands-on-biotechnology-labs-to-secondary-school-students/2015-10-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/10/amgen-announces-2015-fourth-quarter-dividend/2015-10-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/10/amgen-and-labcentral-announce-2015-golden-ticket-winners/2015-10-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/10/new-data-show-consistent-safety-profile-for-up-to-10-years-with-prolia-denosumab-in-postmenopausal-women-with-osteoporosis/2015-10-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/10/new-exploratory-analysis-showed-romosozumab-increased-estimated-bone-strength-more-than-teriparatide/2015-10-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/10/new-data-show-greater-bone-mineral-density-gains-with-prolia-denosumab-compared-with-zoledronic-acid/2015-10-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/10/amgen-announces-repatha-co-preferred-position-on-express-scripts-national-formulary/2015-10-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/10/amgen-to-give-23-presentations-on-osteoporosis-disease-and-treatment-at-american-society-for-bone-and-mineral-research-annual-meeting/2015-10-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/10/amgen-to-present-at-the-barclays-biosimilars-symposium/2015-10-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/09/amgen-receives-chmp-positive-opinions-for-two-new-treatment-options-for-patients-with-blood-cancer-in-europe/2015-09-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/09/amgen-to-present-new-kyprolis-carfilzomib-data-at-15th-international-myeloma-workshop/2015-09-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/09/amgen-and-allergan-announce-positive-top-line-results-from-phase-3-study-of-biosimilar-candidate-abp-215/2015-09-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/09/fda-grants-priority-review-for-amgens-supplemental-new-drug-application-for-expanded-labeling-of-kyprolis-carfilzomib-in-relapsed-multiple-myeloma/2015-09-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/09/amgen-to-acquire-privately-held-dezima-pharma/2015-09-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/09/amgen-and-xencor-announce-strategic-collaboration-in-cancer-immunotherapy-and-inflammation/2015-09-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference/2015-09-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/09/amgen-highlights-key-clinical-data-to-be-presented-at-european-cancer-congress-2015/2015-09-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference/2015-09-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/09/amgen-submits-application-to-fda-for-new-delivery-option-for-monthly-administration-of-repatha-evolocumab/2015-09-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/09/amgen-submits-marketing-authorization-application-for-novel-intravenous-calcimimetic-etelcalcetide-amg-416-to-the-european-medicines-agency/2015-09-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/09/amgen-enters-into-neuroscience-collaboration-with-novartis-for-alzheimers-disease-and-migraine-programs/2015-09-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/09/amgen-and-ucb-announce-positive-top-line-results-from-open-label-phase-3-study-of-romosozumab-compared-with-teriparatide/2015-09-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/08/fda-approves-amgens-new-cholesterollowering-medication-repatha-evolocumab/2015-08-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/08/amgen-to-present-new-longterm-repatha-evolocumab-data-analysis-at-esc-congress-2015/2015-08-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/08/amgen-submits-new-drug-application-for-novel-intravenous-calcimimetic-etelcalcetide-amg-416/2015-08-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/08/amgen-and-university-of-california-berkeley-announce-multiyear-partnership-to-assist-cancer-patient-advocacy-organizations-in-measuring-effectiveness-of-programs/2015-08-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/07/amgen-announces-appointment-of-fred-hassan-to-board-of-directors/2015-07-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/07/amgens-second-quarter-2015-revenues-increased-4-percent-to-54-billion-and-adjusted-earnings-per-share-eps-increased-8-percent-to-257/2015-07-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/07/amgen-announces-2015-third-quarter-dividend/2015-07-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/07/amgen-announces-webcast-of-2015-second-quarter-financial-results/2015-07-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/07/fda-approves-kyprolis-carfilzomib-for-combination-use-in-the-treatment-of-patients-with-relapsed-multiple-myeloma/2015-07-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/07/amgen-submits-supplemental-new-drug-application-for-kyprolis-carfilzomib-in-relapsed-multiple-myeloma/2015-07-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/07/european-commission-approves-amgens-new-cholesterollowering-medication-repatha-evolocumab-the-first-pcsk9-inhibitor-to-be-approved-in-the-world-for-treatment-of-high-cholesterol/2015-07-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/07/amgen-announces-positive-blincyto-blinatumomab-phase-2-study-results-in-patients-with-relapsedrefractory-philadelphia-chromosomepositive-bcell-precursor-acute-lymphoblastic-leukemia/2015-07-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/06/amgen-presents-open-label-extension-data-from-ongoing-phase-2-study-of-amg-334-in-the-prevention-of-episodic-migraine/2015-06-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/06/results-from-phase-3-trial-show-vectibix-panitumumab-improves-overall-survival-in-chemorefractory-wildtype-kras-metastatic-colorectal-cancer-versus-best-supportive-care/2015-06-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/06/amgen-to-discuss-details-of-repatha-evolocumab-biologics-license-application-for-the-treatment-of-high-cholesterol/2015-06-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/06/amgen-to-present-at-the-goldman-sachs-global-healthcare-conference/2015-06-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/06/amgen-completes-enrollment-in-large-cardiovascular-outcomes-trial-of-repatha-evolocumab-in-patients-with-high-cholesterol-and-clinically-evident-cardiovascular-disease/2015-06-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/06/amgen-announces-collaboration-with-roche-on-cancer-immunotherapy-study-with-investigational-medicines-talimogene-laherparepvec-and-atezolizumab/2015-06-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/06/amgen-presents-phase-3-data-at-asco-showing-prolia-denosumab-significantly-reduced-bone-fractures-in-breast-cancer-patients-receiving-aromatase-inhibitors/2015-06-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgen-initiates-phase-3-study-evaluating-onceweekly-kyprolis-carfilzomib-in-patients-with-relapsed-and-refractory-multiple-myeloma/2015-05-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgen-and-merck-announce-expansion-of-collaboration-to-support-studies-of-talimogene-laherparepvec-in-combination-with-keytruda-pembrolizumab-in-patients-with-head-and-neck-cancer/2015-05-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgen-presents-pooled-phase-3-amg-416-data-for-the-treatment-of-secondary-hyperparathyroidism-in-patients-with-chronic-kidney-disease/2015-05-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgen-launches-program-to-further-advance-basic-biology-research/2015-05-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgen-to-present-at-the-jefferies-2015-global-healthcare-conference/2015-05-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgen-to-advance-understanding-of-the-treatment-of-blood-cancers-at-20th-congress-of-european-hematology-association-eha/2015-05-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/pivotal-study-results-published-in-journal-of-clinical-oncology-showed-talimogene-laherparepvec-improved-durable-response-rates-in-patients-with-metastatic-melanoma/2015-05-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgen-to-terminate-participation-in-co-development-and-commercialization-of-brodalumab/2015-05-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgen-receives-positive-chmp-opinion-for-use-of-repatha-evolocumab-for-the-treatment-of-high-cholesterol/2015-05-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgen-appoints-jonathan-p-graham-senior-vice-president-general-counsel-and-secretary/2015-05-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgen-presents-first-phase-2-data-for-amg-334-in-the-prevention-of-episodic-migraine/2015-05-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders/2015-05-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgen-data-at-asco-2015-highlight-oncology-pipeline-and-portfolio/2015-05-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgens-breakaway-from-cancer-announces-winners-of-its-nationwide-search-for-champions-in-the-fight-against-cancer/2015-05-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgen-to-present-amg-334-data-at-17th-congress-of-the-international-headache-society/2015-05-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/05/amgen-to-present-at-the-deutsche-bank-40th-annual-healthcare-conference/2015-05-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/04/amgen-announces-fda-advisory-committee-meeting-to-review--repatha-evolocumab-as-a-treatment-for-high-cholesterol/2015-04-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/04/amgen-to-discuss-details-of-the-biologics-license-application-for-talimogene-laherparepvec-for-patients-with-metastatic-melanoma/2015-04-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/04/amgens-first-quarter-2015-revenues-increased-11-percent-to-50-billion-and-adjusted-earnings-per-share-eps-increased-33-percent-to-248/2015-04-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/04/amgen-announces-webcast-of-2015-first-quarter-financial-results/2015-04-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/04/fda-approves-corlanor-ivabradine-to-reduce-the-risk-of-hospitalization-for-worsening-heart-failure-in-patients-with-chronic-heart-failure/2015-04-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/04/european-commission-approves-amgens-vectibix-panitumumab-as-firstline-treatment-in-combination-with-folfiri-chemotherapy-for-metastatic-colorectal-cancer/2015-04-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/03/amgen-to-present-at-the-goldman-sachs-key-debates-in-biosimilars-conference/2015-03-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/03/fda-grants-amgen-priority-review-for-kyprolis-carfilzomib-supplemental-new-drug-application-for-the-treatment-of-relapsed-multiple-myeloma/2015-03-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/03/cancer-survivor-joan-lunden-named-2015-honorary-breakaway-from-cancer-champion-and-joins-nationwide-search-for-ten-champions-in-the-fight-against-cancer/2015-03-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/03/the-genomic-portrait-of-a-nation/2015-03-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/03/amgen-to-webcast-investor-call-at-the-73rd-annual-meeting-of-the-american-academy-of-dermatology/2015-03-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/03/amgen-submits-application-for-investigational-ldl-cholesterollowering-medication-repatha-evolocumab-in-japan/2015-03-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/03/amgen-to-present-10-abstracts-from-its-dermatology-portfolio-at-the-73rd-annual-meeting-of-the-american-academy-of-dermatology/2015-03-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/03/amgen-publishes-safety-analysis-of-investigational-cholesterollowering-medication-repatha-evolocumab-in-the-new-england-journal-of-medicine/2015-03-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/03/new-detailed-data-from-phase-3-study-show-amgens-repatha-evolocumab-in-combination-with-statins-reduced-ldlc-by-6776-percent-compared-to-placebo-in-japanese-patients-with-high-cardiovascular-risk-and-high-cholesterol/2015-03-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/03/amgen-announces-2015-second-quarter-dividend/2015-03-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/03/amgen-showcases-cardiovascular-pipeline-at-acc-15-with-new-cholesterol-lowering-and-chronic-heart-failure-data/2015-03-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/03/amgen-announces-launch-of-new-neulasta-pegfilgrastim-delivery-kit/2015-03-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/03/phase-3-headtohead-endeavor-study-demonstrates-superiority-of-kyprolis-carfilzomib-over-velcade-bortezomib-in-patients-with-relapsed-multiple-myeloma/2015-03-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/02/amgen-receives-positive-chmp-opinion-for-use-of-vectibix-panitumumab-as-firstline-treatment-in-combination-with-folfiri-chemotherapy-for-advanced-colorectal-cancer/2015-02-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/02/amgen-announces-the-european-medicines-agency-acceptance-of-kyprolis-carfilzomib-marketing-authorization-application-for-the-treatment-of-relapsed-multiple-myeloma/2015-02-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/02/amgen-announces-positive-results-from-head-to-head-study-comparing-the-efficacy-and-safety-of-amg-416-with-cinacalcet-in-patients-with-secondary-hyperparathyroidism-receiving-hemodialysis/2015-02-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/02/amgen-to-present-at-the-cowen-and-company-35th-annual-health-care-conference/2015-02-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/02/amgen-announces-fda-advisory-committees-to-review-talimogene-laherparepvec-for-the-treatment-of-patients-with-metastatic-melanoma/2015-02-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/02/amgen-announces-positive-top-line-results-from-phase-3-study-evaluating-the-efficacy-and-safety-of-biosimilar-candidate-abp-501-compared-with-adalimumab-in-patients-with-moderate-to-severe-rheumatoid-arthritis/2015-02-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/01/amgen-the-familial-hypercholesterolemia-foundation-and-stanford-medicine-launch-find-fh-initiative-to-improve-diagnosis-and-care-for-people-with-familial-hypercholesterolemia/2015-01-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/01/amgen-submits-applications-in-the-us-and-europe-for-kyprolis-carfilzomib-for-the-treatment-of-relapsed-multiple-myeloma/2015-01-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/01/amgens-2014-revenues-increased-7-percent-to-201-billion-and-adjusted-earnings-per-share-eps-increased-14-percent-to-870/2015-01-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/01/amgen-announces-webcast-of-2014-fourth-quarter-and-full-year-financial-results/2015-01-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/01/amgen-presents-new-data-supporting-firstline-use-of-vectibix-panitumumab-in-combination-with-folfox-in-patients-with-wildtype-ras-metastatic-colorectal-cancer/2015-01-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/01/amgen-and-md-anderson-announce-agreement-to-develop-bite-therapies-for-myelodysplastic-syndrome/2015-01-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/01/amgen-to-present-at-the-33rd-annual-j-p--morgan-healthcare-conference/2015-01-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2015/01/amgen-and-kite-pharma-announce-strategic-cancer-immunotherapy-collaboration-to-advance-the-application-of-novel-chimeric-antigen-receptor-car-t-cell-therapies/2015-01-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/12/amgen-joins-with-labcentral-to-support-lifesciences-and-biotech-startups-in-cambridge-massachusetts/2014-12-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/12/amgen-announces-30-percent-increase-in-2015-first-quarter-dividend/2014-12-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/12/amgen-and-astrazeneca-to-present-results-from-phase-3-amagine-1-study-evaluating-brodalumab-in-patients-with-moderate-to-severe-plaque-psoriasis/2014-12-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/12/amgen-presents-data-from-pivotal-phase-2-study-of-blincyto-blinatumomab-immunotherapy-in-patients-with-relapsedrefractory-acute-lymphoblastic-leukemia/2014-12-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/12/new-trial-initiated-evaluating-amgens-talimogene-laherparepvec-in-combination-with-mercks-antipd1-therapy-keytruda-pembrolizumab-for-advanced-melanoma/2014-12-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/12/fda-approves-amgens-xgeva-denosumab-for-the-treatment-of-hypercalcemia-of-malignancy-refractory-to-bisphosphonate-therapy/2014-12-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/12/amgen-announces-new-data-from-phase-2-blincyto-blinatumomab-immunotherapy-study-in-patients-with-acute-lymphoblastic-leukemia-and-minimal-residual-disease/2014-12-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/12/amgen-and-onyx-announce-detailed-results-from-phase-3-aspire-study-of-kyprolis-carfilzomib-in-patients-with-relapsed-multiple-myeloma/2014-12-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/12/amgen-to-webcast-investor-meeting-at-upcoming-american-society-of-hematology-ash-56th-annual-meeting-and-exposition/2014-12-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/12/actress-adamari-lpez-and-amgen-launch-spanish-language-chemotherapy-myths-or-facts-website-and-resources/2014-12-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/12/fda-approves-blincyto-blinatumomab-immunotherapy-for-the-treatment-of-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukemia/2014-12-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/11/amgen-and-astrazeneca-announce-positive-results-from-third-and-final-pivotal-phase-3-study-of-brodalumab-in-patients-with-moderate-to-severe-plaque-psoriasis/2014-11-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/11/amgen-announces-termination-of-all-amgen-sponsored-clinical-studies-of-rilotumumab-in-advanced-gastric-cancer/2014-11-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/11/amgen-presents-long-term-data-showing-efficacy-and-safety-of-investigational-cholesterol-lowering-medication-evolocumab-across-lipid-and-ldl-c-levels/2014-11-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/11/amgen-to-present-at-the-jefferies-global-healthcare-conference/2014-11-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/11/amgen-to-webcast-investor-call-at-upcoming-american-heart-association-scientific-sessions/2014-11-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/11/amgen-to-highlight-new-data-for-investigational-cholesterol-lowering-medication-evolocumab/2014-11-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/11/the-amgen-foundation-expands-amgen-scholars-program-to-17-top-educational-institutions-worldwide/2014-11-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/11/amgen-and-astrazeneca-announce-positive-results-from-second-pivotal-phase-3-study-of-brodalumab-in-patients-with-moderate-to-severe-plaque-psoriasis/2014-11-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/11/fda-accepts-amgens-biologics-license-application-for-ldl-cholesterollowering-medication-evolocumab/2014-11-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/11/amgen-to-present-at-the-credit-suisse-annual-healthcare-conference/2014-11-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/11/amgen-highlights-new-data-in-the-treatment-of-blood-cancers-at-ash-2014/2014-11-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/11/amgen-announces-top-line-secondary-endpoint-results-of-phase-3-trebananib-trinova-1-trial-in-patients-with-recurrent-ovarian-cancer/2014-11-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/10/amgen-outlines-strategy-growth-objectives-and-capital-allocation-plans/2014-10-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/10/amgens-third-quarter-2014-revenues-increased-6-percent-to-50-billion-and-adjusted-earnings-per-share-eps-increased-19-percent-to-230/2014-10-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/10/amgen-to-webcast-2014-business-review-meeting-on-october-28/2014-10-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/10/amgen-announces-webcast-of-2014-third-quarter-financial-results/2014-10-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/10/amgen-statement-regarding-third-point-investment/2014-10-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/10/amgen-announces-appointment-of-r--sanders-williams-to-board-of-directors/2014-10-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/10/amgen-announces-2014-fourth-quarter-dividend/2014-10-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/10/amgen-files-lawsuit-against-sanofi-and-regeneron-for-patent-infringement/2014-10-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/10/amgens-bite-immunotherapy-blinatumomab-receives-fda-priority-review-designation-in-acute-lymphoblastic-leukemia/2014-10-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/10/amgen-announces-positive-top-line-results-from-phase-3-study-evaluating-the-efficacy-and-safety-of-biosimilar-candidate-abp-501-compared-with-adalimumab-in-patients-with-moderate-to-severe-plaque-psoriasis/2014-10-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/10/the-lancet-publishes-two-phase-3-studies-showing-cholesterol-lowering-medication-evolocumab-significantly-reduced-ldl-cholesterol-in-patients-with-serious-genetic-disorders-that-cause-high-cholesterol/2014-10-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/10/amgen-announces-moderate-to-severe-plaque-psoriasis-data-to-be-presented-at-the-23rd-congress-of-the-european-academy-of-dermatology-and-venereology/2014-10-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/09/amgen-to-host-summary-webcast-of-kyprolis-carfilzomib-for-injection-data-presented-at-the-european-society-for-medical-oncology-esmo-2014-congress/2014-09-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/09/amgen-submits-biologics-license-application-for-investigational-bite-immunotherapy-blinatumomab/2014-09-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/09/amgen-foundation-commits-2-million-to-support-science-teachers-across-europe/2014-09-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/09/amgen-announces-results-from-several-new-exploratory-analyses-evaluating-longterm-impact-of-treatment-with-prolia-denosumab-in-postmenopausal-women-with-osteoporosis/2014-09-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/09/new-analyses-of-phase-2-study-presented-at-asbmr-show-romosozumab-treatment-resulted-in-continued-increases-in-bone-mineral-density/2014-09-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/09/amgen-presents-analyses-of-phase-3-ivabradine-data-for-the-treatment-of-chronic-heart-failure/2014-09-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/09/amgen-announces-23-abstracts-to-be-presented-at-the-american-society-for-bone-and-mineral-research-2014-annual-meeting/2014-09-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference/2014-09-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/09/amgen-submits-marketing-authorization-application-for-talimogene-laherparepvec-to-the-european-medicines-agency/2014-09-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/09/amgen-submits-marketing-authorization-application-for-novel-investigational-ldl-cholesterol-lowering-medication-evolocumab-to-the-european-medicines-agency/2014-09-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/08/amgen-announces-positive-top-line-results-from-phase-3-yukawa-2-trial-of-evolocumab-in-combination-with-statins-in-japanese-patients-with-high-cardiovascular-risk-and-high-cholesterol/2014-08-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/08/amgen-submits-biologics-license-application-for-novel-investigational-ldl-cholesterol-lowering-medication-evolocumab-to-the-fda/2014-08-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/08/fda-grants-amgen-priority-review-designation-for-ivabradine-for-the-treatment-of-chronic-heart-failure/2014-08-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/08/amgen-names-elliott-m-levy-md-senior-vice-president-global-development/2014-08-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/08/amgen-announces-positive-top-line-results-from-second-phase-3-study-of-amg-416-for-the-treatment-of-secondary-hyperparathyroidism-in-patients-with-chronic-kidney-disease-receiving-hemodialysis/2014-08-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/08/amgen-issues-voluntary-recall-of-aranesp-darbepoetin-alfa-500-mcg-prefilled-syringes-in-several-countries-outside-of-the-united-states-due-to-the-presence-of-visible-particulates/2014-08-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/08/amgen-announces-top-line-results-from-phase-3-focus-trial-of-kyprolis-in-patients-with-relapsed-and-advanced-refractory-multiple-myeloma/2014-08-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/08/amgen-announces-phase-3-aspire-trial-of-kyprolis-in-patients-with-relapsed-multiple-myeloma-met-primary-endpoint/2014-08-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/07/amgens-second-quarter-2014-revenues-increased-11-percent-to-52-billion-and-adjusted-earnings-per-share-eps-increased-25-percent-to-237/2014-07-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/07/amgen-announces-2014-third-quarter-dividend/2014-07-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/07/amgen-announces-webcast-of-2014-second-quarter-financial-results/2014-07-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/07/amgen-announces-positive-phase-3-results-for-amg-416-for-the-treatment-of-secondary-hyperparathyroidism-in-patients-with-chronic-kidney-disease-receiving-hemodialysis/2014-07-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/07/amgen-receives-fda-breakthrough-therapy-designation-for-investigational-bite-antibody-blinatumomab-in-acute-lymphoblastic-leukemia/2014-07-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/06/amgen-joins-the-national-cancer-institute-and-research-partners-to-help-accelerate-development-of-personalized-treatment-approaches-for-squamous-cell-lung-cancer/2014-06-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/06/brodalumab-treatment-improved-clinical-signs-and-symptoms-in-phase-2-psoriatic-arthritis-study-published-in-the-new-england-journal-of-medicine/2014-06-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/06/amgen-appoints-david-w--meline-executive-vice-president-and-chief-financial-officer/2014-06-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/06/amgen-to-present-at-the-goldman-sachs-global-healthcare-conference/2014-06-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/06/amgen-presents-new-data-on-talimogene-laherparepvec-as-single-agent-and-combination-therapy-in-metastatic-melanoma-at-asco/2014-06-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/06/new-detailed-phase-3-data-show-amgens-novel-investigational-cholesterollowering-medication-evolocumab-significantly-reduced-ldl-cholesterol-in-patients-with-a-rare-and-serious-genetic-disorder-that-causes-high-cholesterol/2014-06-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/05/amgen-highlights-phase-2-results-of-vectibix-panitumumab-versus-bevacizumab-in-combination-with-folfox-in-patients-with-wildtype-ras-kras-and-nras-metastatic-colorectal-cancer/2014-05-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/05/amgen-to-present-at-the-jefferies-2014-global-healthcare-conference/2014-05-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/05/amgen-to-host-postamerican-society-of-clinical-oncology-asco-summary-webcast/2014-05-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/05/amgen-and-onyx-data-at-asco-2014-highlight-oncology-pipeline-and-portfolio/2014-05-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/05/fda-approves-firstline-use-of-vectibix-panitumumab-plus-folfox-for-patients-with-wildtype-kras-metastatic-colorectal-cancer/2014-05-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/05/the-new-england-journal-of-medicine-publishes-positive-proof-of-concept-data-for-new-asthma-treatment/2014-05-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders/2014-05-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/05/journal-of-the-american-medical-association-publishes-phase-3-laplace-2-study-showing-evolocumab-significantly-reduced-ldl-cholesterol-in-patients-on-statins-regardless-of-statin-dose/2014-05-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/05/amgens-breakaway-from-cancer-honors-four-california-cancer-survivors-during-the-ninth-annual-amgen-tour-of-california/2014-05-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/05/amgen-names-steven-k-galson-senior-vice-president-global-regulatory-affairs-and-safety/2014-05-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/05/amgen-and-astrazeneca-announce-positive-results-from-phase-3-study-of-brodalumab-amg-827-in-patients-with-moderatetosevere-plaque-psoriasis/2014-05-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/05/amgen-to-present-at-the-deutsche-bank-39th-annual-healthcare-conference/2014-05-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/04/amgens-first-quarter-2014-revenues-increased-7-percent-to-45-billion/2014-04-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/04/amgen-announces-webcast-of-2014-first-quarter-financial-results/2014-04-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/04/amgen-provides-update-on-phase-3-study-of-talimogene-laherparepvec-in-patients-with-metastatic-melanoma/2014-04-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/03/data-from-phase-3-pivotal-studies-show-amgens-novel-investigational-cholesterollowering-medication-evolocumab-significantly-reduced-ldl-cholesterol-in-statin-intolerant-patients-and-in-patients-on-statins/2014-03-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/03/new-detailed-data-from-three-phase-3-pivotal-studies-show-amgens-novel-investigational-cholesterollowering-medicine-evolocumab-significantly-reduced-ldl-cholesterol-by-5566-percent-compared-to-placebo-in-patients-with-high-cholesterol/2014-03-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/03/amgen-to-webcast-investor-meeting-at-upcoming-american-college-of-cardiologys-63rd-annual-scientific-session/2014-03-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/03/phase-3-pivotal-data-on-amgens-novel-investigational-cholesterollowering-medicine-to-be-featured-at-the-american-college-of-cardiologys-63rd--annual-scientific-session/2014-03-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/03/amgen-announces-positive-topline-results-from-phase-3-tesla-trial-of-evolocumab-amg-145-in-patients-with-homozygous-familial-hypercholesterolemia/2014-03-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/03/amgens-talimogene-laherparepvec-reduced-size-of-melanoma-tumors-in-new-phase-3-retrospective-analysis/2014-03-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/03/amgen-names-david-piacquad-senior-vice-president-business-development/2014-03-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/03/bayer-and-onyx-report-phase-3-study-results-of-nexavar-sorafenib-as-adjuvant-treatment-for-patients-with-liver-cancer-who-have-undergone-surgery-or-local-ablation/2014-03-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/03/amgen-announces-2014-second-quarter-dividend/2014-03-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/03/amgen-to-present-at-the-cowen-and-company-34th-annual-healthcare-conference/2014-03-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/02/amgen-to-present-at-the-rbc-capital-markets-global-healthcare-conference/2014-02-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/02/amgen-and-merck-announce-collaboration-to-evaluate-investigational-combination-treatment-for-advanced-melanoma/2014-02-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/01/amgen-announces-positive-topline-results-from-phase-3-rutherford2-trial-of-evolocumab-amg-145-in-patients-with-heterozygous-familial-hypercholesterolemia/2014-01-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/01/amgen-announces-positive-topline-results-from-phase-3-laplace2-trial-of-evolocumab-amg-145-in-combination-with-statins-in-patients-with-high-cholesterol/2014-01-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/01/amgens-2013-revenues-increased-8-percent-to-187-billion-and-adjusted-earnings-per-share-eps-increased-17-percent-to-760/2014-01-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/01/amgen-announces-webcast-of-2013-fourth-quarter-and-full-year-financial-results/2014-01-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/01/amgen-announces-positive-topline-results-from-phase-3-gauss2-trial-of-evolocumab-amg-145-in-statin-intolerant-patients-with-high-cholesterol/2014-01-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/01/mass-general-broad-institute-and-amgen-will-work-to-discover-new-drugs-for-inflammatory-bowel-disease/2014-01-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/01/amgen-to-present-at-the-32nd-annual-j-p--morgan-healthcare-conference/2014-01-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/01/chief-financial-officer-jonathan-m-peacock-to-leave-amgen-company-appoints-michael-a-kelly-acting-chief-financial-officer/2014-01-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2014/01/romosozumab-phase-2-data-published-in-new-england-journal-of-medicine-show-significant-increases-in-bone-mineral-density-at-both-spine-and-hip/2014-01-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/12/amgen-announces-positive-topline-results-from-52week-phase-3-descartes-study-of-evolocumab-amg-145-in-patients-with-high-cholesterol/2013-12-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/12/amgen-announces-positive-topline-results-from-phase-3-mendel2-trial-of-evolocumab-amg-145-in-patients-with-high-cholesterol/2013-12-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/12/amgen-announces-2014-first-quarter-dividend/2013-12-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/12/amgen-to-host-post-american-society-of-hematology-ash-summary-webcast/2013-12-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/11/us-fda-approves-nexavar-sorafenib-for-the-treatment-of-patients-with-locally-recurrent-or-metastatic-progressive-differentiated-thyroid-carcinoma-refractory-to-radioactive-iodine-treatment/2013-11-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/11/amgen-statement-on-analyst-comments-concerning-kyprolis-trial-data/2013-11-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/11/amgen-announces-evolocumab-amg-145-results-from-first-52week-study-of-a-pcsk9-inhibitor-to-reduce-ldl-cholesterol/2013-11-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/11/amgen-presents-interim-overall-survival-data-from-phase-3-study-of-talimogene-laherparepvec-in-patients-with-metastatic-melanoma/2013-11-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/11/amgen-to-webcast-investor-meeting-at-upcoming-american-heart-association-scientific-sessions-2013/2013-11-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/11/amgen-to-highlight-new-evolocumab-amg-145-data-at-upcoming-american-heart-association-scientific-sessions-2013/2013-11-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/11/amgen-to-present-at-the-credit-suisse-annual-healthcare-conference/2013-11-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/11/amgen-and-onyx-pharmaceuticals-announce-upcoming-data-presentations-at-55th-american-society-of-hematology-annual-meeting/2013-11-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/11/amgen-foundation-commits-25-million-in-new-grants-to-engage-50000-students-each-year-in-the-thrill-of-scientific-inquiry/2013-11-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/10/amgen-promotes-two-senior-executives-names-brian-mcnamee-executive-vice-president-and-stuart-tross-senior-vice-president/2013-10-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/10/amgens-third-quarter-2013-revenues-increased-10-percent-to-47-billion-and-adjusted-earnings-per-share-eps-increased-16-percent-to-194/2013-10-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/10/amgen-acquires-filgrastim-franchise-rights-from-roche-in-100-markets/2013-10-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/10/amgen-announces-webcast-of-2013-third-quarter-financial-results/2013-10-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/10/amgen-announces-appointment-of-greg-c--garland-to-board-of-directors/2013-10-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/10/amgen-announces-2013-fourth-quarter-dividend/2013-10-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/10/amgen-presents-nearly-two-dozen-abstracts-from-romosozumab-and-prolia-denosumab-at-asbmr/2013-10-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/10/amgen-and-astrazeneca-highlight-data-to-be-presented-at-22nd-congress-of-the-european-academy-of-dermatology-and-venereology/2013-10-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/10/amgen-successfully-completes-onyx-pharmaceuticals-tender-offer/2013-10-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/09/amgen-presents-new-data-from-phase-3-study-of-talimogene-laherparepvec-in-patients-with-metastatic-melanoma/2013-09-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/09/phase-3-trial-comparing-vectibix-panitumumab-to-erbitux-cetuximab-meets-primary-endpoint-of-noninferiority-of-overall-survival/2013-09-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/09/amgen-and-shanghaitech-university-announce-plans-for-amgen-china-rd-center-to-open-on-shanghaitech-campus/2013-09-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/09/amgen-and-onyx-pharmaceuticals-announce-early-termination-of-hsr-waiting-period-for-amgens-acquisition-of-onyx/2013-09-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/09/amgen-highlights-data-to-be-presented-at-2013-european-cancer-congress/2013-09-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/09/analysis-published-in-new-england-journal-of-medicine-highlights-discovery-of-new-predictive-biomarkers-for-vectibix-panitumumab/2013-09-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference/2013-09-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference/2013-09-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/09/amgen-and-cytokinetics-announce-the-first-presentation-of-data-from-phase-2-atomic-ahf-study-of-omecamtiv-mecarbil/2013-09-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/09/amgen-presents-pooled-analysis-showing-amg-145-significantly-reduced-ldl-cholesterol-in-over-1200-patients/2013-09-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/08/amgen-to-participate-at-citis-8th-annual-biotech-conference/2013-08-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/08/amgen-to-highlight-new-data-at-upcoming-esc-congress-2013/2013-08-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/08/amgen-to-acquire-onyx-pharmaceuticals-for-$125-per-share-in-cash/2013-08-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/08/amgen-and-servier-complete-product-collaboration-transaction/2013-08-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/07/amgens-second-quarter-2013-revenues-increased-5-percent-to-47-billion-and-adjusted-earnings-per-share-eps-increased-3-percent-to-189/2013-07-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/07/amgen-announces-2013-third-quarter-dividend/2013-07-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/07/amgen-announces-webcast-of-2013-second-quarter-financial-results/2013-07-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/07/the-lancet-oncology-publishes-results-of-xgeva-denosumab-in-patients-with-giant-cell-tumor-of-bone/2013-07-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/07/amgen-and-servier-announce-product-collaboration/2013-07-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/06/amgen-award-for-science-teaching-excellence-honors-outstanding-teachers/2013-06-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/06/fda-approves-amgens-xgeva-denosumab-for-the-treatment-of-giant-cell-tumor-of-bone/2013-06-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/06/amgen-announces-topline-results-of-phase-3-trebananib-amg-386-trinova1-trial-in-recurrent-ovarian-cancer/2013-06-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/06/amgen-and-astrazeneca-highlight-data-to-be-presented-at-european-league-against-rheumatism-annual-meeting/2013-06-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/06/amgen-and-cytokinetics-announce-expansion-of-license-for-omecamtiv-mecarbil/2013-06-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/06/amgen-to-present-at-the-goldman-sachs-34th-annual-global-healthcare-conference/2013-06-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/06/amgen-presents-positive-results-from-talimogene-laherparepvec-phase-3-study-in-patients-with-metastatic-melanoma/2013-06-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/05/amgen-to-webcast-investor-meeting-at-upcoming-american-society-of-clinical-oncology-annual-meeting/2013-05-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/05/amgen-and-astellas-announce-japan-alliance/2013-05-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/05/amgen-to-present-at-the-deutsche-bank-38th-annual-healthcare-conference/2013-05-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders/2013-05-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/05/amgen-to-present-at-the-ubs-global-life-sciences-conference/2013-05-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/05/new-analyses-identify-predictive-biomarkers-for-vectibix-panitumumab-in-patients-with-metastatic-colorectal-cancer/2013-05-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/05/amgen-highlights-data-to-be-presented-at-american-society-of-clinical-oncology-annual-meeting/2013-05-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/05/amgen-and-zhejiang-beta-pharma-announce-planned-joint-venture-in-china/2013-05-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/05/amgen-announces-topline-results-of-vectibix-panitumumab-phase-3-headtohead-study-against-erbitux-cetuximab-in-metastatic-colorectal-cancer/2013-05-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/05/four-californians-selected-as-breakaway-from-cancer-champions-to-be-honored-during-amgen-tour-of-california/2013-05-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/04/amgens-first-quarter-2013-revenues-increased-5-percent-to-42-billion-and-adjusted-earnings-per-share-eps-increased-22-percent-to-196/2013-04-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/04/amgen-announces-webcast-of-2013-first-quarter-financial-results/2013-04-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/03/amgen-announces-top-line-results-of-phase-3-talimogene-laherparepvec-trial-in-melanoma/2013-03-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/03/amgen-announces-2013-second-quarter-dividend/2013-03-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/03/amgen-to-present-at-the-cowen-and-company-33rd-annual-health-care-conference/2013-03-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/02/amgen-statement-on-government-budget-analysis-for-oral-only-treatments-for-dialysis-patients/2013-02-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/02/amgen-announces-call-for-nominations-for-2013-breakaway-from-cancer-champions/2013-02-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/02/amgen-outlines-long-term-strategy/2013-02-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/01/amgen-to-webcast-2013-business-review-meeting-on-february-7/2013-01-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/01/amgen-announces-results-from-phase-3-paves-study-evaluating-neulasta-pegfilgrastim-in-patients-with-colorectal-cancer/2013-01-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/01/amgen-backs-states-efforts-to-enact-biosimilar-legislation-that-allows-for-substitution-and-supports-patient-safety/2013-01-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/01/amgens-full-year-2012-revenues-increased-11-percent-to-173-billion-and-adjusted-earnings-per-share-eps-increased-22-percent-to-651/2013-01-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/01/amgen-announces-webcast-of-2012-fourth-quarter-and-full-year-financial-results/2013-01-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/01/amgen-announces-topline-results-of-phase-3-aranesp-darbepoetin-alfa-redhf-trial/2013-01-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/01/amgen-to-build-state-of-the-art-manufacturing-facility-in-singapore/2013-01-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2013/01/amgen-to-present-at-the-31st-annual-j-p--morgan-global-healthcare-conference/2013-01-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/12/amgen-finalizes-agreement-resolving-previously-announced-federal-investigations/2012-12-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/12/amgen-announces-appointment-of-robert-a--eckert-to-board-of-directors/2012-12-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/12/amgen-names-robert-a--bradway-chairman-of-the-board-of-directors/2012-12-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/12/amgen-announces-31-percent-increase-in-2013-first-quarter-dividend-and-increase-in-its-share-repurchase-authorization/2012-12-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/12/amgen-to-acquire-decode-genetics-a-global-leader-in-human-genetics/2012-12-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/12/amgen-highlights-data-to-be-presented-at-american-society-of-hematology-annual-meeting/2012-12-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/11/amgen-to-present-at-the-24th-annual-piper-jaffray-healthcare-conference/2012-11-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/11/amgen-and-pfizer-highlight-data-to-be-presented-at-american-college-of-rheumatology-meeting/2012-11-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/11/the-lancet-publication-of-laplace-timi-57-and-mendel-studies-showed-amg-145-significantly-reduced-ldl-cholesterol/2012-11-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/11/circulation-publishes-results-from-rutherford-study-which-showed-amg-145-significantly-reduced-ldl-cholesterol-in-patients-with-heterozygous-familial-hypercholesterolemia/2012-11-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/11/journal-of-the-american-medical-association-publishes-amg-145-phase-2-gauss-study-showing-significant-reductions-in-ldl-cholesterol-in-statin-intolerant-patients/2012-11-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/11/phase-3-sensiparmimpara-evolvetm-trial-published-in-the-new-england-journal-of-medicine/2012-11-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/11/amgen-to-present-data-from-four-phase-2-studies-at-upcoming-american-heart-association-scientific-sessions-2012/2012-11-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/11/amgen-to-webcast-investor-meeting-at-upcoming-american-heart-association-scientific-sessions-2012/2012-11-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/10/amgens-third-quarter-2012-revenues-increased-10-percent-to-43-billion-and-adjusted-earnings-per-share-eps-increased-19-percent-to-167/2012-10-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/10/amgen-announces-webcast-of-2012-third-quarter-financial-results/2012-10-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/10/amgen-presents-several-sub-analyses-at-asbmr-from-the-ongoing-open-label-extension-study-of-the-pivotal-phase-3-prolia-fracture-trial/2012-10-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/10/amgen-appoints-cynthia-patton-senior-vice-president-and-chief-compliance-officer/2012-10-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/10/amgen-announces-2012-fourth-quarter-dividend/2012-10-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/09/fda-approves-new-indication-for-prolia-denosumab-for-the-treatment-of-bone-loss-in-men-with-osteoporosis-at-high-risk-for-fracture/2012-09-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/09/amgen-names-ray-jordan-senior-vice-president-corporate-affairs/2012-09-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference/2012-09-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference/2012-09-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/08/amgen-to-present-at-the-baird-healthcare-conference/2012-08-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/08/amgen-announces-termination-of-ganitumab-phase-3-study-for-futility-in-metastatic-pancreatic-cancer/2012-08-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/07/amgens-second-quarter-2012-revenues-increased-13-percent-to-45-billion-and-adjusted-earnings-per-share-eps-increased-34-percent-to-183/2012-07-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/07/amgen-announces-webcast-of-2012-second-quarter-financial-results/2012-07-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/07/amgen-announces-2012-third-quarter-dividend/2012-07-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/07/amgen-completes-acquisition-of-kai-pharmaceuticals/2012-07-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/06/actress-maura-tierney-and-amgen-launch-the-chemotherapy-myths-or-facts-tm-campaign/2012-06-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/06/amgen-completes-acquisition-of-mustafa-nevzat-pharmaceuticals/2012-06-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/06/20th-annual-amgen-award-for-science-teaching-excellence-honors-nine-outstanding-teachers/2012-06-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/06/amgen-announces-topline-results-of-phase-3-sensiparmimpara-evolvetm-trial/2012-06-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders/2012-05-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/05/amgens-bite-antibody-blinatumomab-amg-103-achieved-high-rate-of-complete-response-in-adult-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia/2012-05-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/05/analysis-of-rilotumumab-amg-102-data-identifies-a-potential-predictive-biomarker-for-patients-with-gastric-or-gastroesophageal-cancer/2012-05-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/05/amgen-to-provide-testimony-at-fda-stakeholder-hearing-on-biosimilars/2012-05-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/05/cancer-support-community-launches-national-program-to-assist-patients-with-cancer-make-informed-decisions-about-care/2012-05-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/05/amgen-to-present-at-the-baird-growth-stock-conference/2012-05-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/05/amgen-to-present-at-the-deutsche-bank-37th-annual-healthcare-conference/2012-05-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/05/cure-magazine-announces-winner-of-the-2012-extraordinary-healer-award-for-oncology-nursing/2012-05-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/05/four-californians-selected-as-breakaway-from-cancer-champions-to-be-honored-during-amgen-tour-of-california/2012-05-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/04/amgen-receives-complete-response-letter-from-fda-for-xgeva-sbla-for-prevention-of-bone-metastases/2012-04-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/04/amgen-to-acquire-mustafa-nevzat-a-leading-privately-held-turkish-pharmaceutical-company/2012-04-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/04/amgens-first-quarter-2012-revenue-increased-9-percent-to-40-billion-and-adjusted-earnings-per-share-eps-increased-20-percent-to-161/2012-04-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/04/a-tribute-to-george-rathmann-amgens-founding-ceo-19272012/2012-04-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/04/amgen-announces-webcast-of-2012-first-quarter-financial-results/2012-04-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/04/amgen-to-acquire-privately-held-kai-pharmaceuticals/2012-04-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/04/ucb-and-amgen-initiate-sclerostin-antibody-phase-3-program-in-patients-with-postmenopausal-osteoporosis/2012-04-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/04/amgen-and-astrazeneca-announce-collaboration-to-jointly-develop-and-commercialize-clinical-stage-inflammation-portfolio/2012-04-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/03/amgen-announces-phase-2-study-results-for-brodalumab-in-moderate-to-severe-plaque-psoriasis-published-in-the-new-england-journal-of-medicine/2012-03-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/03/amgens-pcsk9-inhibitor-reduced-ldl-cholesterol-up-to-81-percent-in-phase-1b-study/2012-03-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/03/amgen-announces-2012-second-quarter-dividend/2012-03-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/03/amgen-completes-tender-offer-for-outstanding-shares-of-micromet-inc/2012-03-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/03/schwartz-center-receives-500000-grant-from-the-amgen-foundation/2012-03-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/03/amgen-announces-initial-results-of-tender-offer-for-outstanding-shares-of-micromet-inc-and-commencement-of-subsequent-offering-period/2012-03-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/02/amgen-to-present-at-the-cowen-and-company-32nd-annual-healthcare-conference/2012-02-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/02/amgen-and-european-schoolnet-launch-new-professional-development-initiative-for-life-science-teachers/2012-02-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/02/amgen-to-present-at-the-citi-2012-global-healthcare-conference/2012-02-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/02/cure-magazine-teams-up-with-amgen-oncology-and-breakaway-from-cancer-to-launch-2012-extraordinary-healer-award-for-oncology-nursing/2012-02-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/02/amgen-and-micromet-announce-early-termination-of-hsr-waiting-period-for-amgens-acquisition-of-micromet/2012-02-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/02/amgen-names-michael-severino-md-senior-vice-president-global-development-and-corporate-chief-medical-officer/2012-02-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/02/amgen-to-present-at-the-leerink-swann-global-healthcare-conference/2012-02-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/02/amgen-to-discuss-application-for-new-use-of-xgeva-denosumab-at-fda-oncologic-drugs-advisory-committee-meeting/2012-02-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/01/amgens-full-year-2011-revenue-increased-4-percent-to-156-billion-and-adjusted-earnings-per-share-eps-increased-2-percent-to-533/2012-01-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/01/amgen-to-acquire-micromet/2012-01-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/01/amgen-announces-webcast-of-2011-fourth-quarter-and-full-year-financial-results/2012-01-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2012/01/amgen-to-present-at-the-30th-annual-j-p--morgan-global-healthcare-conference/2012-01-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/12/fda-to-review-potential-new-use-of-xgeva-denosumab-at-oncologic-drugs-advisory-committee-meeting/2011-12-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/12/amgen-and-watson-announce-collaboration-to-develop-and-commercialize-oncology-biosimilars/2011-12-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/12/kevin-sharer-amgen-chairman-and-ceo-announces-plan-to-retire-with-robert-bradway-to-become-ceo-on-may-23-2012-sharer-will-continue-as-chairman-of-the-board-until-end-of-2012/2011-12-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/12/amgen-announces-2012-first-quarter-dividend/2011-12-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/12/amgen-announces-final-results-of-its-tender-offer/2011-12-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/12/amgen-presents-final-results-from-the-largest-phase-3-openlabel-study-assessing-the-safety-and-efficacy-of-nplate-romiplostim/2011-12-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/12/amgen-to-present-at-the-22nd-annual-oppenheimer-healthcare-conference/2011-12-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/12/amgen-announces-preliminary-results-of-its-tender-offer/2011-12-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/12/amgen-and-fda-agree-to-modify-nplate-romiplostim-risk-evaluation-and-mitigation-strategy/2011-12-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/11/enbrel-etanercept-patent-issued/2011-11-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/11/the-lancet-publishes-results-demonstrating-xgeva-significantly-prolonged-bone-metastasis-free-survival-in-men-with-prostate-cancer/2011-11-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/11/vectibix-panitumumab-granted-approval-for-expanded-indications-in-the-european-union/2011-11-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/11/amgen-statement-on-european-investor-visit/2011-11-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/11/amgen-announces-plan-to-launch-tender-offer-and-launch-of-senior-notes-offering/2011-11-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/11/prolia-denosumab-openlabel-extension-trial-showed-continued-increase-in-bone-mineral-density-over-six-years-with-similar-safety-profile-observed-in-original-fracture-trial/2011-11-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/11/treatment-with-enbrel-etanercept-shows-significant-and-sustained-clinical-benefits-in-rheumatoid-arthritis-ra-patients-with-moderately-active-disease/2011-11-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/10/amgens-third-quarter-2011-revenue-and-adjusted-earnings-per-share-eps-each-increased-3-percent-to-39-billion-and-140/2011-10-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/10/amgen-announces-webcast-of-2011-third-quarter-financial-results/2011-10-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/10/amgen-appoints-anthony-tony-hooper-executive-vice-president-global-commercial-operations/2011-10-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/10/amgen-appoints-robert-a-bradway-to-the-companys-board-of-directors/2011-10-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/10/amgen-announces-2011-fourth-quarter-dividend/2011-10-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/09/amgen-highlights-data-to-be-presented-at-2011-european-multidisciplinary-cancer-congress/2011-09-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/09/fda-approves-new-indications-for-prolia-denosumab-for-the-treatment-of-bone-loss-in-patients-with-prostate-or-breast-cancer-undergoing-hormone-ablation-therapy/2011-09-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/09/prolia-denosumab-phase-2-extension-study-showed-continued-increase-in-bone-mineral-density-over-eight-years-of-treatment/2011-09-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/09/amgen-to-present-at-the-ubs-global-life-sciences-conference/2011-09-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/09/amgen-staff-volunteer-efforts-result-in-5000-for-each-of-their-favorite-nonprofits/2011-09-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference/2011-09-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-conference/2011-09-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/09/amgen-to-present-at-the-baird-healthcare-conference/2011-09-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/09/amgen-to-present-at-the-stifel-nicolaus-healthcare-conference/2011-09-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/08/awardwinning-actress-blythe-danner-and-amgen-launch-act-2-reduce-fracturestm-educational-campaign/2011-08-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/08/amgen-announces-pdufa-date-for-xgeva-supplemental-biologics-license-application/2011-08-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/08/amgen-highlights-data-to-be-presented-at-american-society-for-bone-and-mineral-research-meeting/2011-08-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/07/amgens-second-quarter-2011-revenue-increased-4-percent-to-40-billion/2011-07-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/07/amgen-announces-webcast-of-2011-second-quarter-financial-results/2011-07-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/07/amgen-resolves-g-csf-patent-litigation-with-teva/2011-07-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/07/xgeva-denosumab-granted-marketing-authorization-in-the-european-union/2011-07-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/07/amgen-and-ucb-team-up-with-nasa-on-final-space-shuttle-mission-to-conduct-preclinical-test-of-sclerostin-antibody-on-bone-loss/2011-07-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/06/amgen-submits-application-to-expand-indication-for-xgeva-denosumab-to-prevent-or-delay-spread-of-prostate-cancer-to-the-bone/2011-06-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/06/notice-to-investors-regarding-2011-and-2015-guidance/2011-06-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/06/amgen-announces-modifications-to-u-s--prescribing-information-for-use-of-erythropoiesis-stimulating-agents-in-chronic-kidney-disease/2011-06-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/06/amgen-receives-positive-chmp-opinion-for-vectibix-panitumumab-in-combination-with-chemotherapy/2011-06-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/06/teachers-and-schools-across-north-america-receive-10000-amgen-award-for-science-teaching-excellence/2011-06-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/05/data-presented-at-two-global-medical-congresses-reinforce-benefit-of-enbrelr-etanercept-for-patients-with-chronic-inflammatory-conditions/2011-05-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders/2011-05-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/05/amgen-receives-chmp-positive-opinion-for-xgevatm-denosumab-in-the-european-union/2011-05-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/05/amgen-oncology-data-to-be-presented-at-asco-annual-meeting/2011-05-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/05/phase-3-data-demonstrate-xgevatm-denosumab-is-first-bone-targeted-therapy-to-prevent-spread-of-cancer-to-the-bone-in-men-with-advanced-prostate-cancer/2011-05-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/05/amgen-to-webcast-investor-meeting-at-upcoming-american-urological-association-conference/2011-05-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/05/patrick-dempsey-teams-up-with-breakaway-from-cancerr-to-help-connect-cancer-patients-to-free-resources/2011-05-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/05/five-californians-selected-as-breakaway-from-cancerr-champions-to-be-honored-during-amgen-tour-of-california/2011-05-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/04/amgen-to-present-at-the-deutsche-bank-36th-annual-healthcare-conference/2011-04-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/04/amgen-outlines-strategy-growth-objectives-and-capital-allocation-plans/2011-04-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/04/amgen-and-ucb-announce-positive-phase-2-results-of-amg-785cdp7851-in-patients-with-postmenopausal-osteoporosis-pmo/2011-04-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/04/amgens-first-quarter-2011-revenue-increased-3-percent-to-37-billion/2011-04-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/04/amgen-to-webcast-2011-business-review-meeting-on-april-21/2011-04-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/04/amgen-announces-webcast-of-2011-first-quarter-financial-results/2011-04-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/04/amgen-establishes-commercial-operations-in-brazil/2011-04-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/03/amgen-to-appeal-chmp-opinion-on-vectibixr-panitumumab-use-with-chemotherapy-in-metastatic-colorectal-cancer-in-europe/2011-03-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/03/top-line-results-announced-of-pivotal-phase-3-motesanib-trial-in-advanced-non-squamous-non-small-cell-lung-cancer-patients/2011-03-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/03/proliar-denosumab-openlabel-extension-trial-showed-continued-increase-in-bone-mineral-density-over-five-years-of-treatment-with-similar-safety-profile-observed-in-pivotal-trial/2011-03-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/03/treatment-with-proliar-denosumab-associated-with-significantly-greater-adherence-compliance-and-persistence-compared-to-alendronate/2011-03-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/03/amgen-statement-on-chmp-opinion-on-vectibixr-panitumumab-use-with-chemotherapy-in-metastatic-colorectal-cancer/2011-03-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/03/amgen-donates-$1-million-to-help-japanese-disaster-victims/2011-03-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/03/amgen-completes-acquisition-of-biovex/2011-03-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/03/amgen-to-present-at-the-cowen-and-company-31st-annual-healthcare-conference/2011-03-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/03/breakaway-from-cancerr-launches-newlyenhanced-website-offering-comprehensive-tailored-support-for-cancer-patients/2011-03-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/03/worldclass-professional-golfer-phil-mickelson-launches-on-course-with-phil-for-people-with-certain-inflammatory-joint-and-skin-conditions/2011-03-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/03/nbpts-and-amgen-foundation-join-to-bolster-science-education/2011-03-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/02/results-published-in-the-lancet-demonstrate-superiority-of-xgevatm-denosumab-in-the-prevention-of-bone-complications-for-men-with-bone-metastases-from-advanced-prostate-cancer/2011-02-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/02/amgen-to-present-at-the-citi-2011-global-healthcare-conference/2011-02-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/02/the-journal-of-clinical-oncology-publishes-phase-3-xgevatm-denosumab-results-in-advanced-cancer-patients-with-solid-tumors-or-multiple-myeloma/2011-02-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/02/enbrelr-etanercept-significantly-improved-scalp-involvement-in-patients-with-moderate-to-severe-plaque-psoriasis/2011-02-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/01/amgen-to-acquire-biovex-a-privately-held-biotechnology-company-headquartered-in-woburn-mass/2011-01-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/01/amgens-fourth-quarter-2010-adjusted-earnings-per-share-increased-11-percent-to-117-full-year-2010-adjusted-earnings-per-share-increased-6-percent-to-521/2011-01-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/01/amgen-announces-webcast-of-2010-fourth-quarter-and-full-year-financial-results/2011-01-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/01/boehringer-ingelheim-to-purchase-amgens-fremont-california-facility/2011-01-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/01/sensiparr-patents-upheld-by-district-court/2011-01-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/01/amgen-to-present-at-the-29th-annual-jp-morgan-healthcare-conference/2011-01-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2011/01/amgen-and-xencor-enter-option-deal-to-codevelop-xencors-novel-antibody-for-autoimmune-diseases/2011-01-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/12/teach-for-america-and-the-amgen-foundation-renew-partnership-to-improve-math-and-science-education-in-urban-and-rural-schools/2010-12-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/12/xgevatm-denosumab-significantly-improved-bone-metastasisfree-survival-in-men-with-prostate-cancer/2010-12-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/12/amgen-presents-new-xgevatm-denosumab-breast-cancer-skeletalrelated-event-prevention-data-at-sabcs/2010-12-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/12/amgen-to-present-at-deutsche-banks-2010-biofest/2010-12-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/12/three-innovative-ideas-receive-10000-prizes-in-patients--choices--empowerment-competition/2010-12-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/12/amgens-nplater-maintains-platelet-counts-for-more-than-five-years-in-adults-with-chronic-itp/2010-12-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/12/amgen-highlights-data-to-be-presented-at-american-society-of-hematology-annual-meeting/2010-12-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/11/fda-approves-amgens-xgevatm-denosumab-for-the-prevention-of-skeletalrelated-events-in-patients-with-bone-metastases-from-solid-tumors/2010-11-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/11/amgen-foundation-and-ashokas-changemakers-announce-finalists-in-patients--choices--empowerment-competition/2010-11-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/11/call-for-applications-the-amgen-award-for-science-teaching-excellence/2010-11-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/11/amgen-foundation-recognizes-outstanding-staff-volunteers-and-contributes-55000-to-their-favorite-local-nonprofits/2010-11-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/11/study-published-in-new-england-journal-of-medicine-shows-nplater-significantly-reduces-treatment-failure-and-splenectomy-rate-in-patients-with-chronic-itp/2010-11-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/11/amgen-scholars-undergraduate-summer-research-program-begins-phase-2/2010-11-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/11/amgen-to-present-at-19th-annual-credit-suisse-healthcare-conference/2010-11-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/11/published-results-show-denosumab-superior-to-zometar-in-delaying-or-preventing-bone-complications-in-patients-with-bone-metastases-from-advanced-breast-cancer/2010-11-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/11/amgen-pfizer-and-worldclass-professional-golfer-phil-mickelson-announce-partnership/2010-11-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/11/proliatm-denosumab-receives-best-new-drug-honor-at-scrip-awards/2010-11-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/11/amgen-foundation-awards-45-million-grant-to-mla-partner-schools-to-invest-in-las-promise/2010-11-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/11/amgen-to-provide-testimony-at-fda-hearing-on-biosimilars/2010-11-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/10/amgens-third-quarter-2010-revenue-unchanged-at-38-billion-versus-prior-year/2010-10-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/10/breakaway-from-cancerr-launches-striking-the-balance-podcast-series-to-inspire-action-and-change-across-the-cancer-continuum/2010-10-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/10/amgen-announces-webcast-of-2010-third-quarter-financial-results/2010-10-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/10/amgen-to-review-results-from-treat-and-propose-updates-to-esa-labeling-for-chronic-renal-failure-patients-at-an-fda-advisory-committee-meeting-today/2010-10-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/10/amgen-highlights-data-to-be-presented-at-american-society-for-bone-and-mineral-research-asbmr-meeting/2010-10-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/10/integrated-analysis-demonstrates-that-denosumab-delays-the-onset-of-bone-complications-compared-to-zometar/2010-10-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/10/updated-amg-386-data-demonstrate-promising-antitumor-activity-in-patients-with-recurrent-ovarian-cancer/2010-10-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/10/amgen-highlights-key-clinical-data-to-be-presented-at-european-society-for-medical-oncology-congress/2010-10-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/10/two-pivotal-vectibixr-phase-3-studies-in-first-and-secondline-treatment-of-metastatic-colorectal-cancer-published-in-the-journal-of-clinical-oncology/2010-10-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/09/amgen-initiates-voluntary-nationwide-recall-of-certain-lots-of-epogenr-and-procritr-epoetin-alfa/2010-09-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/09/amgen-and-pfizer-introduce-psophisticated-style-a-guide-to-everyday-style-and-psoriasistm-hosted-by-tim-gunn/2010-09-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/09/amgen-to-present-at-the-ubs-global-life-sciences-conference/2010-09-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference/2010-09-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/09/amgen-to-present-at-the-baird-healthcare-conference/2010-09-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/08/amgen-announces-top-line-results-of-phase-3-head-and-neck-cancer-trial/2010-08-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/07/amgens-second-quarter-2010-adjusted-earnings-per-share-increased-7-percent-to-138/2010-07-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/07/2010-addressing-psoriasistm-contest-winners-attend-a-style-consultation-with-tim-gunn-in-new-york-city/2010-07-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/07/amgen-announces-webcast-of-2010-second-quarter-financial-results/2010-07-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/07/amgen-appoints-ronald-d-sugar-to-the-companys-board-of-directors/2010-07-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/07/amgen-scholars-summer-research-helps-lead-to-science-careers/2010-07-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/07/fda-grants-priority-review-designation-to-denosumab-biologics-license-application-for-the-reduction-of-skeletal-related-events-in-advanced-cancer-patients/2010-07-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/07/amgen-appoints-jonathan-m--peacock-executive-vice-president-and-chief-financial-officer/2010-07-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/07/amgen-foundation-and-changemakers-launch-global-online-competition-to-empower-patients-for-better-outcomes/2010-07-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/06/34-teachers-and-schools-across-north-america-receive-10000-amgen-award-for-science-teaching-excellence/2010-06-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/06/amgen-to-present-at-the-goldman-sachs-global-healthcare-conference/2010-06-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/06/amgen-to-present-at-the-jeffries-global-life-sciences-conference/2010-06-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/06/new-amg-386-data-demonstrate-promising-antitumor-activity-in-patients-with-recurrent-ovarian-cancer/2010-06-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/06/striking-the-balance-community-experts-come-together-for-high-level-dialogue-on-cancer-care/2010-06-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/06/denosumab-demonstrated-superiority-over-zometar-in-delay-of-complications-due-to-bone-metastases-in-advanced-prostate-cancer/2010-06-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/06/new-analyses-of-denosumab-pivotal-phase-3-trials-reinforce-potential-advantages-over-standard-of-care/2010-06-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/06/new-amg-479-phase-2-data-show-antitumor-activity-in-patients-with-metastatic-pancreatic-cancer/2010-06-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/06/fda-approves-amgens-proliatm-denosumab-for-treatment-of-postmenopausal-women-with-osteoporosis-at-high-risk-for-fracture/2010-06-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/05/proliar-denosumab-granted-marketing-authorization-in-the-european-union/2010-05-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/05/amgen-highlights-key-clinical-data-to-be-presented-at-american-society-of-clinical-oncology-annual-meeting/2010-05-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/05/amgen-submits-denosumab-biologics-license-application-to-fda-for-the-reduction-of-skeletal-related-events-in-cancer-patients/2010-05-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders/2010-05-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/05/amgens-breakaway-from-cancerr-to-honor-cancer-survivors-at-amgen-tour-of-california/2010-05-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/05/amgen-scientists-visit-biotechnology-classrooms-across-the-country-in-support-of-national-lab-day/2010-05-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/04/amgen-to-present-at-the-deutsche-bank-35th-annual-healthcare-conference/2010-04-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/04/amgen-appoints-robert-a--bradway-president-and-chief-operating-officer/2010-04-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/04/amgens-first-quarter-2010-adjusted-earnings-per-share-increased-20-percent-to-130/2010-04-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/04/amgen-announces-webcast-of-2010-first-quarter-financial-results/2010-04-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/04/amgen-preclinical-study-demonstrated-anti-tumor-activity-in-mammary-tumor-model/2010-04-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/04/analysis-of-vectibixr-study-using-new-gene-technology-helps-to-advance-prospects-for-personalized-medicine/2010-04-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/04/amgen-highlights-biomarker-and-preclinical-data-to-be-presented-at-american-association-for-cancer-research-aacr-annual-meeting/2010-04-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/03/amgen-to-present-at-the-cowen-and-company-30th-annual-healthcare-conference/2010-03-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/03/project-runways-tim-gunn-returns-to-address-psoriasistm-and-empower-patients-to-be-confident-in-their-personal-style/2010-03-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/02/fda-classifies-proliatm-denosumab-complete-response-submission-and-targets-action-date/2010-02-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/02/amgen-and-centocor-ortho-biotech-products-finalize-esa-risk-evaluation-and-mitigation-strategy-rems-with-fda/2010-02-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/02/denosumab-demonstrated-superiority-over-zometar-in-pivotal-phase-3-headtohead-trial-in-prostate-cancer-patients-with-bone-metastases/2010-02-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/01/amgens-fourth-quarter-2009-adjusted-earnings-per-share-decreased-1-percent-to-105-full-year-2009-adjusted-earnings-per-share-increased-8-percent-to-491/2010-01-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/01/amgen-presents-complete-results-from-two-pivotal-phase-3-studies-of-vectibixr-at-gastrointestinal-cancers-symposium/2010-01-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/01/amgen-announces-webcast-of-2009-fourth-quarter-and-full-year-financial-results/2010-01-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/01/amgen-donates-2-million-establishes-earthquake-relief-program/2010-01-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2010/01/amgen-to-present-at-the-28th-annual-jp-morgan-healthcare-conference/2010-01-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/12/amgen-resolves-epo-patent-dispute-with-roche/2009-12-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/12/amgens-roger-m-perlmutter-md-phd-named-2009-aaas-fellow-recognized-for-discovery-development-of-novel-medicines/2009-12-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/12/amgen-receives-chmp-positive-opinion-for-proliatm-denosumab-in-the-european-union/2009-12-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/12/array-biopharma-and-amgen-partner-in-type-2-diabetes/2009-12-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/12/new-study-results-presented-at-2009-san-antonio-breast-cancer-symposium-show-importance-of-protecting-your-bones/2009-12-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/12/data-presented-at-san-antonio-breast-cancer-symposium-demonstrate-treatment-with-denosumab-is-superior-to-the-standard-of-care/2009-12-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/12/amgen-presents-data-from-first-nplater-study-in-children-with-chronic-itp/2009-12-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/12/amgen-board-authorizes-$5-billion-increase-in-stock-repurchase-program/2009-12-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/12/nplater-data-from-mds-studies-presented-at-ash/2009-12-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/12/new-amgen-scholars-web-site-launches-to-build-a-global-network-for-future-scientists/2009-12-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/11/amgen-highlights-data-to-be-presented-at-ash/2009-11-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/11/amgen-recognized-for-best-pipeline-and-best-new-drug-at-scrip-awards/2009-11-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/11/amgen-to-present-at-lazard-capital-healthcare-conference/2009-11-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/11/amgen-to-present-at-18th-annual-credit-suisse-healthcare-conference/2009-11-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/11/amgen-announces-overall-survival-results-for-vectibixr-in-firstline-metastatic-colorectal-cancer/2009-11-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/11/call-for-applications-the-amgen-award-for-science-teaching-excellence/2009-11-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/10/large-study-of-anemia-treatment-in-chronic-kidney-disease-patients-not-on-dialysis-published-in-the-new-england-journal-of-medicine-failed-to-meet-primary-efficacy-endpoints/2009-10-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/10/amgens-third-quarter-2009-adjusted-earnings-per-share-increased-21-percent-to-149/2009-10-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/10/amgen-provides-update-on-status-of-proliatm-denosumab-biologics-license-application-bla-submitted-to-the-us-food-and-drug-administration-fda/2009-10-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/10/enbrelr-etanercept-data-to-be-presented-at-the-2009-american-college-of-rheumatology-scientific-meeting/2009-10-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/10/amgen-announces-webcast-of-2009-third-quarter-financial-results/2009-10-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/vectibixr-in-combination-with-chemotherapy-significantly-improves-progressionfree-survival-in-firstline-metastatic-colorectal-cancer/2009-09-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/denosumab-demonstrates-superiority-over-zometar-in-delay-of-complications-due-to-bone-metastases-in-advanced-breast-cancer-patients/2009-09-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/vectibixr-in-combination-with-chemotherapy-significantly-improves-progressionfree-survival-in-secondline-metastatic-colorectal-cancer/2009-09-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/phase-3-trial-shows-denosumab-delayed-skeletal-related-events-in-advanced-cancer-patients-with-bone-metastases/2009-09-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/amgen-to-present-at-the-ubs-global-life-sciences-conference/2009-09-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/amgen-to-present-pivotal-data-from-four-phase-3-studies-at-the-ecco-15---esmo-34-congress/2009-09-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/amgen-scholars-europe-programme-convenes-undergraduates-from-15-countries-for-innovative-science-research/2009-09-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/appeals-court-affirms-patent-infringement-rulings-against-roches-pegepo-product/2009-09-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/amgen-to-present-at-the-bank-of-america-merrill-lynch-global-healthcare-conference/2009-09-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/data-show-medication-adherence-is-an-important-factor-in-the-treatment-of-postmenopausal-osteoporosis/2009-09-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-unplugged-conference/2009-09-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/amgen-highlights-data-to-be-presented-at-american-society-for-bone-and-mineral-research-asbmr-meeting/2009-09-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/edie-falco-and-cynthia-nixon-appear-in-new-stand-up-to-cancertm-psas-designed-to-educate-cancer-patients-about-the-importance-of-lowering-ones-risk-of-infection-during-treatment/2009-09-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/amgen-named-presenting-sponsor-of-the-dempsey-challenge-a-journey-for-hope/2009-09-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/amgen-to-present-at-the-thomas-weisel-healthcare-conference/2009-09-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/amgen-to-present-at-the-baird-healthcare-conference/2009-09-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/09/tim-gunn-hosts-addressing-psoriasistm-fashion-show-to-raise-awareness-of-psoriasis/2009-09-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/08/amgen-announces-topline-results-of-trial-to-reduce-cardiovascular-events-with-aranespr-therapy-treat-in-ckd-patients-with-type2-diabetes/2009-08-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/08/vectibixr-significantly-improved-progressionfree-survival-in-secondline-treatment-of-kras-wildtype-metastatic-colorectal-cancer/2009-08-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/08/amgen-issues-statement-on-outcomes-of-advisory-committee-for-reproductive-health-drugs-acrhd-meeting/2009-08-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/08/amgen-to-discuss-denosumab-data-at-todays-advisory-committee-for-reproductive-health-drugs/2009-08-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/08/studies-published-in-the-new-england-journal-of-medicine-highlight-potential-new-option-in-the-treatment-of-bone-loss/2009-08-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/08/vectibixr-in-combination-with-chemotherapy-significantly-improved-progressionfree-survival-in-firstline-metastatic-colorectal-cancer/2009-08-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/08/amgen-and-wyeth-statement-on-fda-announcement-about-tumor-necrosis-factor-tnf-blockers/2009-08-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/08/amgen-announces-positive-topline-results-for-denosumab-in-trial-for-delay-of-skeletal-related-events-in-bone-metastases-patients-compared-to-zometar/2009-08-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/07/amgen-to-collaborate-with-glaxosmithkline-to-commercialize-denosumab-in-europe-for-postmenopausal-osteoporosis-pmo/2009-07-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/07/amgens-second-quarter-2009-adjusted-earnings-per-share-increased-13-percent-to-129/2009-07-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/07/amgen-announces-webcast-of-2009-second-quarter-financial-results/2009-07-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/07/amgen-scholars-discover-their-potential-during-summer-science-research-program-and-national-symposium/2009-07-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/07/amgen-announces-kras-safety-update-to-us-prescribing-information-for-vectibixr-panitumumab/2009-07-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/07/amgen-appoints-rebecca-m-henderson-to-the-companys-board-of-directors/2009-07-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/07/denosumab-demonstrates-superiority-over-zometar-in-pivotal-phase-3-headtohead-trial-in-breast-cancer-patients-with-bone-metastases/2009-07-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/07/winners-of-the-addressing-psoriasistm-contest-selected-to-walk-the-runway-in-new-york-city-fashion-show-hosted-by-tim-gunn/2009-07-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/06/amgen-to-participate-in-reproductive-health-drugs-advisory-committee-meeting-in-august/2009-06-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/06/34-outstanding-teachers-and-schools-receive-10000-amgen-award-for-science-teaching-excellence/2009-06-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/06/amgen-to-present-at-the-goldman-sachs-global-healthcare-conference/2009-06-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/06/new-study-shows-nplater-significantly-reduces-splenectomy-rate-and-treatment-failure-in-patients-with-chronic-itp/2009-06-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/05/video-from-medialink-and-amgen-new-survey-highlights-growing-concern-about-risk-of-infection-and-emerging-antibiotic-resistance-in-cancer-patients/2009-05-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/05/new-survey-highlights-growing-concern-about-risk-of-infection-in-cancer-patients-and-emerging-antibiotic-resistance/2009-05-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/05/amgen-exercises-option-for-exclusive-license-to-cytokinetics-cardiac-contractility-program-that-includes-ck1827452/2009-05-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/05/amgen-highlights-data-to-be-presented-at-asco/2009-05-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/05/amgen-to-present-at-the-deutsche-bank-34th-annual-healthcare-conference/2009-05-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders/2009-05-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/04/amgen-and-onsedge-partner-with-cancer-survivor-jan-ping-for-new-campaign/2009-04-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/04/photos-amgen-and-onsedge-partner-with-cancer-survivor-jan-ping-for-new-campaign/2009-04-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/04/amgens-first-quarter-2009-adjusted-earnings-per-share-decreased-4-percent-to-108/2009-04-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/04/amgen-announces-webcast-of-2009-first-quarter-financial-results/2009-04-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/04/preclinical-data-from-amgens-oncology-pipeline-to-be-presented-at-aacr/2009-04-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/03/amgen-to-present-at-the-citigroup-biotech-day/2009-03-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/03/amgen-to-present-at-the-cowen-and-company-annual-healthcare-conference/2009-03-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/03/amgen-to-present-at-the-barclays-capital-global-healthcare-conference/2009-03-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/03/project-runways-tim-gunn-launches-addressing-psoriasistm-campaign-to-advocate-that-patients-shouldnt-let-psoriasis-impact-personal-style/2009-03-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/02/fda-accepts-amgens-submission-and-files-biologics-license-application-for-denosumab/2009-02-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/02/independent-data-monitoring-committee-recommends-resuming-enrollment-of-non-squamous-nsclc-patients-in-the-motesanib-monet1-trial/2009-02-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/02/nplater-approved-in-the-european-union-for-the-treatment-of-chronic-immune-idiopathic-thrombocytopenic-purpura-itp/2009-02-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/01/amgens-fourth-quarter-2008-adjusted-earnings-per-share-increased-6-percent-to-106-full-year-2008-adjusted-earnings-per-share-increased-6-percent-to-455/2009-01-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/01/amgens-breakaway-from-cancer-initiative-expands-to-help-cancer-patients-access-broad-spectrum-of-cancer-resources-and-services/2009-01-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/01/amgen-announces-webcast-of-2008-fourth-quarter-and-full-year-financial-results/2009-01-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2009/01/amgen-to-present-at-the-27th-annual-jp-morgan-healthcare-conference/2009-01-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/12/amgen-submits-biologics-license-application-for-fda-approval-of-denosumab-in-women-with-postmenopausal-osteoporosis-and-in-patients-undergoing-hormone-ablation-for-either-prostate-or-breast-cancer/2008-12-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/12/oncology-biomarker-kras-to-be-discussed-at-fda-panel-meeting/2008-12-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/12/longterm-follow-up-interim-data-show-nplatetm-increased-and-sustained-platelet-counts-in-adult-chronic-itp-patients/2008-12-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/11/nplatetm-romiplostim-receives-positive-opinion-for-marketing-authorisation-in-the-european-union/2008-11-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/11/amgen-takeda-and-millennium-provide-update-on-phase-3-trial-of-motesanib-in-patients-with-nonsmall-cell-lung-cancer/2008-11-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/11/amgen-foundation-announces-$2-5-million-expansion-of-amgen--scholars-program-to-europe/2008-11-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/11/amgen-positioned-to-deliver-attractive-growth-over-next-five-years/2008-11-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/11/amgen-to-webcast-2008-business-review-meeting-on-november-7-from-millennium-hotel-in-new-york/2008-11-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/11/call-for-applications-the-amgen-award-for-science-teaching-excellence/2008-11-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/10/enbrelr-etanercept-is-the-first-biologic-with-published-efficacy-and-safety-data-for-up-to-a-decade-of-continuous-use-for-the-treatment-of-moderate-to-severe-rheumatoid-arthritis/2008-10-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/10/amgens-third-quarter-2008-adjusted-earnings-per-share-increased-14-percent-to-123/2008-10-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/10/amgen-announces-webcast-of-2008-third-quarter-financial-results/2008-10-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/10/amgen-issues-statement-on-court-of-appeals-ruling-that-affirms-preliminary-injunction-against-roche/2008-10-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/10/amgen-appoints-francois-de-carbonnel-to-the-companys-board-of-directors/2008-10-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/10/district-court-affirms-patent-infringement-rulings-and-finds-that-amgen-is-entitled-to-a-permanent-injunction-against-roche/2008-10-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/09/amgen-receives-executive-summary-from-independent-cochrane-collaboration-review-of-esas-in-oncology/2008-09-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/09/amgen-to-present-at-ubs-global-life-sciences-conference/2008-09-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/09/amgen-to-present-at-the-merrill-lynch-global-pharmaceutical-biotech--medical-devices-conference/2008-09-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/09/denosumab-osteoporosis-trial-finds-patients-transitioned-from-alendronate-fosamaxr-to-denosumab-achieved-significantly-greater-gains-in-bone-mineral-density-versus-those-continuing-on-alendronate/2008-09-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/09/biovitrum-to-acquire-kepivancer-and-stemgenr-and-exclusively-license-kineretr-from-amgen/2008-09-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/09/amgen-to-present-important-clinical-trial-data-at-two-key-congresses/2008-09-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/09/amgen-to-present-at-the-morgan-stanley-global-healthcare-unplugged-conference/2008-09-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/09/amgen-and-wyeth-statement-on-the-fda-safety-announcement-regarding-tumor-necrosis-factor-tnf-blockers/2008-09-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/08/fda-approves-nplatetm-for-longterm-treatment-of-adult-chronic-itp/2008-08-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/07/amgen-licenses-molecule-for-the-treatment-of-chronic-and-neuropathic-pain-to-orthomcneiljanssen-pharmaceuticals-inc/2008-07-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/07/amgen-issues-statement-in-response-to-revised-esa-labeling-received-from-the-fda-today/2008-07-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/07/amgens-second-quarter-2008-adjusted-earnings-per-share-increased-2-percent-to-114/2008-07-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/07/amgen-announces-positive-top-line-results-for-denosumab-pivotal-postmenopausal-osteoporosis-trial/2008-07-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/07/250-amgen-scholars-from-10-premier-universities-convene-for-national-summer-symposium-to-explore-drug-discovery--development/2008-07-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/07/amgen-announces-webcast-of-2008-second-quarter-financial-results/2008-07-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/07/study-showed-half-of-patients-treated-with-enbrelr-etanercept-plus-methotrexate-can-achieve-das-clinical-remission-and-80-percent-had-no-progression-of-joint-damage-in-active-early-rheumatoid-arthritis/2008-07-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/07/amgen-announces-positive-top-line-results-for-denosumab-treatment-of-bone-loss-in-men-with-non-metastatic-prostate-cancer-undergoing-androgen-deprivation-therapy/2008-07-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/07/amgen-and-ortho-biotech-settle-antitrust-suit/2008-07-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/07/amgen-commits-to-phrmas-enhanced-code-on-interactions-with-healthcare-professionals-as-part-of-the-companys-clearly-amgen-initiative/2008-07-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/06/new-data-show-preemptive-treatment-may-significantly-reduce-skin-toxicities-in-patients-receiving-vectibixr-panitumumab/2008-06-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/06/amgen-and-wyeth-statement-on-outcome-of-dermatologic-and-ophthalmic-drugs-advisory-committee-dodac-meeting/2008-06-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/06/enbrelr-etanercept-application-for-the-treatment-of-pediatric-psoriasis-to-be-discussed-at-fda-dermatologic-and-ophthalmic-drugs-advisory-committee-dodac-meeting/2008-06-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/06/romiplostim-data-show-potential-long-term-efficacy-and-safety-in-adults-with-chronic-itp/2008-06-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/06/amgen-svp-of-north-american-commercial-operations-james-daly-to-present-at-the-goldman-sachs-healthcare-conference/2008-06-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/06/amgen-names-anna-richo-senior-vice-president-of-worldwide-compliance/2008-06-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/06/2008-recipients-of-amgen-award-for-science-teaching-excellence-announced/2008-06-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/06/amgen-and-wyeth-statement-on-the-fda-early-communication-about-tumor-necrosis-factor-tnf-blockers/2008-06-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/06/updated-data-from-ongoing-phase-3-trials-support-the-continued-study-of-vectibixr-panitumumab-in-combination-with-standard-chemotherapy/2008-06-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/05/amgen-presents-new-data-at-asco-on-four-investigational-molecules-from-oncology-pipeline/2008-05-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/05/amgen-reports-positive-data-at-asco-from-three-studies-of-denosumab-in-cancer-patients/2008-05-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/05/interim-phase-2-results-of-open-label-clinical-trial-of-denosumab-in-giant-cell-tumor-of-bone-demonstrated-87-percent-response-rate/2008-05-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/05/amgen-to-webcast-investor-meeting-at-upcoming-american-society-of-clinical-oncology-conference/2008-05-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/05/denosumab-achieved-superior-bone-mineral-density-gains-in-headtohead-trial-versus-weekly-alendronate-fosamaxr/2008-05-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/05/amgen-announces-webcast-to-discuss-results-of-denosumab-phase-3-head-to-head-study-versus-alendronate-at-the-upcoming-european-symposium-on-calcified-tissues-conference/2008-05-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/05/amgen-posts-medical-education-and-foundation-grants-and-donations-as-part-of-the-companys-clearly-amgen-initiative/2008-05-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/05/denosumab-osteoporosis-study-meets-primary-and-all-secondary-bone-mineral-density-endpoints-in-alendronate-fosamaxr-transition-study/2008-05-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/05/amgen-highlights-data-to-be-presented-at-asco/2008-05-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/05/amgen-vp-of-investor-relations-arvind-sood-to-present-at-the-baird-growth-stock-conference/2008-05-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders/2008-05-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/05/amgen-to-participate-in-chmp-oncology-scientific-advisory-group-meeting-in-may/2008-05-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/05/amgen-to-participate-in-dermatologic-and-ophthalmic-drugs-advisory-committee-meeting-in-june/2008-05-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/04/amgen-cfo-bob-bradway-to-present-at-the-morgan-stanley-global-healthcare-unplugged-conference/2008-04-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/04/amgens-first-quarter-2008-adjusted-earnings-per-share-increased-4-percent-to-112/2008-04-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/04/amgen-announces-webcast-of-2008-first-quarter-financial-results/2008-04-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/04/amgen-presents-preclinical-and-clinical-data-from-oncology-programs/2008-04-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/04/amgen-scientist-visits-los-angeles-classroom-during-teach-for-america-week/2008-04-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/04/early-data-on-amgens-antiangiogenesis-pipeline-molecules-suggest-biologic-activity-across-tumor-types/2008-04-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/04/amgen-teach-for-america-summit-to-focus-on-strategies-for-advancing-math-and-science-education/2008-04-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/04/amgen-statement-on-romiplostim-pdufa-date/2008-04-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/04/amgens-oncology-pipeline-data-highlighted-at-upcoming-scientific-meeting/2008-04-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/04/national-kidney-foundation-introduces-plan-to-track-patients-in-national-screening-program/2008-04-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/04/pivotal-phase-3-data-show-denosumab-increased-bone-density-at-multiple-skeletal-sites-in-early-and-later-stage-postmenopausal-women/2008-04-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/03/amgen-and-wyeth-announce-updates-to-us-prescribing-information-for-enbrelr/2008-03-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/03/amgen-to-present-at-the-28th-annual-cowen-healthcare-conference-and-the-11th-annual-lehman-brothers-global-healthcare-conference/2008-03-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/03/amgen-to-discuss-benefits-and-risks-of-esa-treatment-for-cancer-patients-with-anemia-due-to-chemotherapy-at-fda-odac-meeting/2008-03-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/03/amgen-statement-on-successful-outcome-of-romiplostim-panel-meeting/2008-03-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/03/amgen-to-discuss-romiplostim-application-at-fda-odac-meeting/2008-03-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/03/amgen-announces-update-to-us-prescribing-information-for-aranespr-and-epogenr/2008-03-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/03/kyowa-hakko-and-amgen-enter-licensing-agreement-for-anti-ccr4-humanized-monoclonal-antibody/2008-03-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/03/the-colon-cancer-alliance-teams-up-with-joan-lunden-for-amgen-sponsored-workshop-series-designed-to-provide-support-to-patients-and-caregivers/2008-03-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/03/eu-commission-approves-updated-prescribing-information-for-aranespr/2008-03-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/03/kras-biomarker-analysis-from-pivotal-vectibixtm-trial-published/2008-03-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/02/amgen-and-takeda-announce-exclusive-collaboration-in-japan-on-up-to-13-amgen-clinical-candidates/2008-02-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/02/new-findings-show-enbrelr-etanercept-significantly-reduced-levels-of-creactive-protein-a-marker-of-inflammation-in-patients-with-moderate-to-severe-plaque-psoriasis/2008-02-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/01/pooled-phase-3-study-of-nplatetm-romiplostim-in-adult-patients-with-chronic-itp-published-in-the-lancet/2008-01-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/01/amgen-statement-on-aranesp-manuscript-in-the-journal-of-clinical-oncology/2008-01-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/01/interim-safety-data-presented-on-vectibixtm-panitumumab-in-combination-with-standard-chemotherapy/2008-01-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/01/amgens-fourth-quarter-2007-adjusted-earnings-per-share-eps-increased-11-percent-to-100-full-year-2007-adjusted-eps-increased-10-percent-to-429/2008-01-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/01/denosumab-osteoporosis-study-met-primary-and-all-secondary-bone-mineral-density-endpoints-in-a-headtohead-comparison-with-weekly-alendronate-fosamaxr/2008-01-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/01/kras-gene-status-may-impact-vectibixtm-panitumumab-efficacy-and-patient-reported-outcomes-in-advanced-colorectal-cancer-patients/2008-01-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/01/amgen-commences-registered-exchange-offer-for-its-senior-floating-rate-notes-due-2008-585-percent-senior-notes-due-2017-and-6375-percent-senior-notes-due-2037/2008-01-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/01/new-study-reports-enbrelr-etanercept-significantly-improved-moderate-to-severe-plaque-psoriasis-in-children-and-adolescents/2008-01-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/01/amgen-announces-webcast-of-2007-fourth-quarter-and-full-year-financial-results/2008-01-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/01/breakaway-from-cancer-public-service-announcement-spreads-support-and-hope/2008-01-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/01/amgen-updates-2007-adjusted-eps-guidance-and-outlines-2008-expense-outlook-at-the-jp-morgan-healthcare-conference/2008-01-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2008/01/amgen-to-present-at-the-26th-annual-jp-morgan-healthcare-conference/2008-01-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/12/pivotal-phase-3-data-show-denosumab-increased-bone-density-throughout-skeleton-in-non-metastatic-breast-cancer-patients-on-adjuvant-aromatase-inhibitor-therapy/2007-12-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/12/pivotal-phase-3-nplatetm-study-in-nonsplenectomized-patients-met-primary-endpoints/2007-12-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/12/pivotal-phase-3-romiplostim-study-in-splenectomized-patients-meets-primary-endpoints/2007-12-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/12/amgen-in-discussions-with-fda-to-update-u-s--prescribing-information-for-esas/2007-12-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/12/vectibixr-approved-in-the-european-union-for-the-treatment-of-metastatic-colorectal-cancer/2007-12-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/12/amgen-foundation-and-leading-universities-invite-college-students-to-apply-for-amgen-scholars-program/2007-12-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/11/amgen-announces-interim-results-of-aranespr-prepare-study-in-breast-cancer-patients/2007-11-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/11/amgen-announces-my-cancer-coach-contest-winners-at-the-college-hoops-classic/2007-11-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/11/amgen-to-provide-new-evidence-as-part-of-a-formal-reconsideration-of-cms-national-coverage-determination-on-esas/2007-11-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/11/amgen-announces-updates-to-the-u-s--prescribing-information-for-esas/2007-11-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/11/new-data-show-that-half-of-patients-with-active-early-rheumatoid-arthritis-achieved-clinical-remission-at-one-year-when-treated-with-enbrelr-etanercept-plus-methotrexate/2007-11-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/11/call-for-applications-the-amgen-award-for-science-teaching-excellence/2007-11-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/10/amgen-foundation-donates-500000-to-aid-in-southern-california-wildfire-relief-efforts/2007-10-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/10/amgens-third-quarter-2007-adjusted-earnings-per-share-increased-4-percent-to-108/2007-10-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/10/jury-rules-roche-infringes-amgens-epo-patents/2007-10-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/10/amgen-announces-webcast-of-2007-third-quarter-financial-results/2007-10-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/10/amgen-and-dompe-biotec-to-combine-commercial-operations-in-italy/2007-10-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/10/amgen-to-postpone-indefinitely-its-plans-for-a-manufacturing-facility-in-ireland/2007-10-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/10/amgen-appoints-vance-d-coffman-to-the-companys-board-of-directors/2007-10-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/09/amgen-provides-update-on-late-stage-and-early-stage-pipeline-at-ubs-global-life-sciences-conference/2007-09-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/09/aranespr-darbepoetin-alfa-approved-for-use-in-all-european-paediatric-patients-with-chronic-renal-failure-anaemia/2007-09-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/09/amgen-receives-proposal-for-amending-eu-prescribing-information-for-aranespr/2007-09-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/09/phase-2-study-suggests-that-extended-dosing-of-aranespr-is-as-efficacious-as-weekly-dosing/2007-09-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/09/new-analysis-suggests-first-cycle-use-of-neulastar-reduces-febrile-neutropenia-hospitalizations-and-chemotherapy-dose-reductions-in-breast-cancer-patients-compared-to-current-practice/2007-09-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/09/aranespr-dahanca-10-study-results-presented-at-ecco-annual-meeting/2007-09-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/09/new-biomarker-data-links-kras-gene-to-vectibixtm-clinical-response/2007-09-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/09/vectibixtm-panitumumab-receives-positive-opinion-for-marketing-authorization-in-the-european-union/2007-09-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/09/amgen-oncology-highlights-upcoming-data-presentations-at-the-2007-european-conference-on-clinical-oncology/2007-09-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/09/amgen-to-review-benefits-risks-of-esa-therapy-in-chronic-renal-failure-patients-at-fda-advisory-committee/2007-09-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/09/aranespr-study-showing-no-negative-impact-on-survival-in-sclc-presented-at-world-conference-on-lung-cancer/2007-09-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/09/amgen-foundation-awards-grant-to-mentor-la-to-help-improve-public-high-school-education-in-los-angeles/2007-09-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/08/court-rules-that-roche-infringes-one-of-amgens-erythropoietin-patents/2007-08-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/08/amgen-restructures-due-to-lower-aranespr-revenues-while-continuing-to-invest-in-innovation-and-future-growth/2007-08-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/08/amgen-to-hold-conference-call-today-after-the-close-of-financial-markets/2007-08-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/08/first-year-amgen-scholars-and-leading-scientists-attend-symposium-to-explore-drug-discovery--development/2007-08-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/08/dennis-fenton-executive-vice-president-of-operations-elects-to-retire-after-25-years-with-amgen/2007-08-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/07/amgen-responds-to-final-cms-national-coverage-determination-on-use-of-erythropoiesis-stimulating-agents-in-oncology/2007-07-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/07/amgens-second-quarter-2007-adjusted-earnings-per-share-increased-7-percent-to-112/2007-07-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/07/amgen-completes-acquisition-of-ilypsa/2007-07-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/07/amgen-completes-acquisition-of-alantos/2007-07-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/07/amgen-board-authorizes-$5-billion-increase-in-stock-repurchase-program/2007-07-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/07/amgen-and-daiichi-sankyo-announce-agreement-for-denosumab-in-japan/2007-07-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/07/amgen-announces-webcast-of-2007-second-quarter-financial-results/2007-07-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/06/ralph-lauren-center-for-cancer-care-and-prevention-receives-$2-5-million-from-the-amgen-foundation-to-launch-national-patient-navigation-training-institute/2007-06-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/06/amgen-submits-testimony-to-house-ways--means-committee/2007-06-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/06/enbrel-safety-data-for-up-to-eight-years-in-patients-with-juvenile-rheumatoid-arthritis-being-presented-at-eular/2007-06-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/06/amgen-to-acquire-alantos-pharmaceuticals-a-private-biotechnology-company-in-cambridge-massachusetts/2007-06-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/06/amgen-to-acquire-ilypsa-a-private-san-francisco-bay-area-biotechnology-company-focused-on-kidney-disease-care/2007-06-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/06/amgen-submits-comments-in-response-to-cms-proposed-national-coverage-decision/2007-06-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/05/amgen-oncology-highlights-upcoming-data-presentations-at-the-american-society-of-clinical-oncology-asco-annual-meeting/2007-05-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/05/amgen-to-appeal-chmp-opinion-on-vectibixtm-panitumumab/2007-05-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/05/amgen-prices-4-billion-of-senior-notes-in-three-series-company-to-purchase-approximately-3-billion-in-common-stock/2007-05-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/05/amgen-to-offer-4-billion-in-three-series-of-senior-notes-company-to-purchase-approximately-3-billion-in-common-stock/2007-05-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/05/amgen-names-david-lacey-md-senior-vice-president-head-of-research/2007-05-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/05/amgen-recommends-rejection-of-mini-tender-offer-by-trc-capital-corporation/2007-05-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/05/amgen-announces-voting-results-of-annual-meeting-of-stockholders/2007-05-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/04/final-vectibixtm-positive-pivotal-phase-3-trial-results-in-metastatic-colorectal-cancer-patients-published/2007-04-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/04/amgens-first-quarter-2007-revenue-increased-15-percent-to-37-billion/2007-04-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/04/aranespr-145-study-shows-no-difference-in-survival-in-patients-with-smallcell-lung-cancer/2007-04-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/04/2007-recipients-of-amgen-award-for-science-teaching-excellence-announced/2007-04-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/04/aranespr-phase-3-study-in-patients-with-active-cancer-not-receiving-concurrent-chemotherapy-or-radiotherapy-presented-at-aacr-annual-meeting/2007-04-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/04/amgen-announces-webcast-of-2007-first-quarter-financial-results/2007-04-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/04/amgen-names-robert-bradway-executive-vice-president-and-chief-financial-officer/2007-04-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/03/amgen-discontinues-vectibixtm-treatment-in-pacce-trial-evaluating-vectibixtm-as-part-of-triple-combination-regimen/2007-03-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/03/amgen-to-present-at-the-lehman-brothers-tenth-annual-global-healthcare-conference/2007-03-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/03/amgen-to-present-at-the-27th-annual-cowen--company-health-care-conference/2007-03-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/03/amgen-announces-update-to-us-prescribing-information-for-aranespr-and-epogenr/2007-03-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/03/prime-minister-tony-blair-opens-major-amgen-development-centre-in-london/2007-03-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/02/amgen-to-participate-in-oncologic-drugs-advisory-committee-in-may/2007-02-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/02/amgen-to-participate-in-goldman-sachs-in-your-office-call/2007-02-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/02/amgen-to-hold-analyst-call-to-discuss-danish-head-and-neck-cancer-dahanca-10-study/2007-02-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/02/amgen-announces-proposals-to-declassify-board-to-be-presented-at-2007-annual-meeting-and-adopts-majority-vote-bylaw/2007-02-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/02/amgen-ceo-kevin-sharer-to-present-at-the-merrill-lynch-global-pharmaceutical-biotechnology--medical-device-conference/2007-02-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/02/survey-indicates-people-with-chronic-moderate-to-severe-plaque-psoriasis-may-be-under-treated/2007-02-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/01/amgen-announces-put-option-for-liquid-yield-option-notes-due-2032-and-zero-coupon-convertible-notes-due-2032/2007-01-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/01/amgens-fourth-quarter-2006-revenue-increased-17-to-38-billion-full-year-2006-revenue-increased-15-to-143-billion/2007-01-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/01/amgen-launches-2007-breakaway-from-cancer-initiative/2007-01-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/01/amgen-announces-webcast-of-2006-fourth-quarter-and-full-year-financial-results/2007-01-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2007/01/cytokinetics-and-amgen-announce-strategic-alliance-in-heart-failure/2007-01-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/12/amgen-announces-$5-billion-stock-repurchase-plan/2006-12-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/12/updated-interim-long-term-follow-up-data-reported-amg-531-dosed-once-weekly-increased-and-sustained-platelet-counts-in-patients-with-immune-platelet-disorder/2006-12-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/12/final-phase-2-data-continue-to-show-promising-results-after-one-year-of-aranespr-treatment-for-anemia-in-patients-with-myelodysplastic-syndromes-mds/2006-12-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/12/data-show-efficacy-of-extended-dosing-of-aranespr-in-the-treatment-of-chemotherapyinduced-anemia/2006-12-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/12/new-phase-2-data-show-promise-of-aranespr-treatment-for-anemia-of-cancer/2006-12-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/12/amgen-submits-testimony-to-house-ways--means-committee/2006-12-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/12/amgen-responds-to-reports-about-use-and-safety-of-epogen-and-aranesp-in-ckd-anemia-therapy/2006-12-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/12/amgen-names-yuji-orihara-president-amgen-kk/2006-12-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/11/colorectal-patients-offered-new-resource-to-help-navigate-treatment-process/2006-11-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/11/district-court-judge-denies-preliminary-injunction-in-ortho-v--amgen-suit/2006-11-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/11/fashion-designer-and-cancer-survivor-carmen-marc-valvo-offers-support/2006-11-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/11/amgen-launches-chemocoachcom-and-my-cancer-coach-contest-in-conjunction-with-sponsorship-of-college-hoops-classic-benefiting-coaches-vs-cancer/2006-11-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/11/data-shows-enbrel-provides-sustained-clinical-improvements-for-people-with-ankylosing-spondylitis-for-up-to-three-years/2006-11-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/11/enbrel-is-the-first-biologic-to-publish-data-showing-safety-and-sustained-efficacy-for-up-to-nine-years-in-patients-with-moderate-to-severe-rheumatoid-arthritis/2006-11-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/11/amg-706-shows-activity-in-phase-2-study-of-patients-with-advanced-imatinib-resistant-gastrointestinal-stromal-tumors/2006-11-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/11/nominations-open-for-the-amgen-award-for-science-teaching-excellence/2006-11-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/10/amgen-completes-acquisition-of-avidia/2006-10-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/10/amgens-third-quarter-2006-adjusted-earnings-per-share-excluding-stock-option-expense-increased-22-percent-to-104/2006-10-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/10/u-s--district-court-denies-roche-motion-to-dismiss-amgen-patent-infringement-lawsuit/2006-10-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/10/amgen-foundation-launches-$25-million-undergraduate-research-program/2006-10-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/10/amgen-receives-complete-response-letter-for-extended-dosing-of-aranespr-for-patients-with-chronic-kidney-disease-and-anemia/2006-10-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/10/amgen-announces-webcast-of-third-quarter-financial-results/2006-10-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/09/amgen-to-acquire-avidia-a-privately-held-biopharmaceutical-company-in-the-san-francisco-bay-area/2006-09-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/09/amgen-introduces-comprehensive-financial-assistance-programs-for-cancer-patients/2006-09-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/09/fda-approves-vectibixtm-to-treat-patients-with-metastatic-colorectal-cancer/2006-09-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/09/amgen-names-thomas-flanagan-senior-vice-president-and-chief-information-officer/2006-09-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/09/amgen-announces-license-agreement-with-yeda-research-and-development-company-ltd-license-agreement-accords-amgen-freedom-to-operate-under-866-patent/2006-09-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/09/amgen-presents-denosumab-and-sclerostin-antibody-data-at-american-society-for-bone-and-mineral-research-annual-meeting-data-suggest-the-potential-for-targeting-the-key-proteins-rank-ligand-and-sclerostin-for-bone-loss-conditions/2006-09-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/09/amgen-launches-aranespr-darbepoetin-alfa-prefilled-sureclicktm-autoinjector-for-treatment-of-anemia-associated-with-chemotherapy-and-chronic-kidney-disease/2006-09-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/08/amgen-wins-tkt-appeal/2006-08-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/07/amgens-second-quarter-2006-adjusted-earnings-per-share-excluding-stock-option-expense-increased-19-percent-to-105-gaap-earnings-per-share-of-1-cent-reflects-11-billion-onetime-writeoff-of-inprocess-rd-related-to-abgenix-acquisition/2006-07-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/07/amgen-update-on-presentation-materials-for-webcast-of-second-quarter-financial-results/2006-07-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/07/amgen-announces-evolve-trialtm-to-investigate-impact-of-sensiparrmimparar-cinacalcet-hcl-on-mortality-and-cardiovascular-morbidity-in-secondary-hyperparathyroidism-patients-with-chronic-kidney-disease-receiving-dialysis/2006-07-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/07/amgen-announces-termination-of-poison-pill-effective-july-31-2006/2006-07-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/07/itc-judge-grants-summary-determination-that-roches-activities-are-covered-by-clinical-trial-exemption/2006-07-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/07/amgen-announces-webcast-of-second-quarter-financial-results/2006-07-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/06/final-results-of-phase-2-clinical-trial-program-suggest-treatment-of-anemia-with-aranespr-darbepoetin-alfa-may-decrease-risk-of-hospitalization-and-allcause-mortality-in-heart-failure-patients-with-anemia-based-on-a-prespecified-pooled-analysis/2006-06-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/06/fda-grants-priority-review-of-panitumumab-for-treatment-of-patients-with-metastatic-colorectal-cancer/2006-06-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/06/phase-2-interim-data-show-denosumab-decreased-bone-turnover-in-advanced-cancer-patients-with-bone-metastases/2006-06-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/06/interim-data-suggest-potential-benefits-of-aranespr-dosed-every-three-weeks-with-intravenous-iron-for-chemotherapyinduced-anemia-94-percent-of-patients-achieved-target-hemoglobin-level/2006-06-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/06/interim-phase-2-aranespr-data-suggest-major-response-after-2728-weeks-of-treatment-for-anemia-in-patients-with-myelodysplastic-syndromes-mds/2006-06-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/06/new-interim-phase-2-data-suggest-the-antitumor-activity-of-panitumumab-in-metastatic-colorectal-cancer/2006-06-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/05/amgen-oncology-highlights-upcoming-data-presentations-at-the-american-society-of-clinical-oncology-annual-meeting-clinical-data-to-be-presented-on-four-investigational-targeted-cancer-therapies/2006-05-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/05/large-headtohead-study-of-aranespr-dosed-every-two-weeks-versus-epoetin-alfa-dosed-weekly-published-in-the-journal-of-clinical-oncology/2006-05-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/05/itc-accepts-amgens-complaint-to-investigate-roches-importation-of-pegepo/2006-05-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/04/alcon-and-amgen-sign-collaboration-agreement-to-develop-and-commercialize-innovative-therapies-in-ophthalmology/2006-04-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/04/amgens-first-quarter-2006-adjusted-earnings-per-share-excluding-stock-option-expense-increased-26-percent-to-91-cents-first-quarter-2006-gaap-earnings-per-share-increased-22-percent-to-82-cents/2006-04-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/04/amgen-files-with-itc-against-roches-importation-of-pegepo/2006-04-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/04/2006-recipients-of-amgen-award-for-science-teaching-excellence-announced-19-outstanding-science-teachers-and-their-schools-recognized-in-amgen-communities-across-the-us-and-puerto-rico/2006-04-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/04/amgen-announces-webcast-of-first-quarter-financial-results/2006-04-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/04/randomized-phase-3-trial-shows-panitumumab-significantly-improved-progression-free-survival-and-disease-control-in-metastatic-colorectal-cancer-patients/2006-04-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/04/amgen-completes-acquisition-of-abgenix-acquisition-provides-amgen-with-full-ownership-of-panitumumab-and-eliminates-a-denosumab-royalty/2006-04-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/03/amgen-and-abgenix-complete-biologics-license-application-for-fda-approval-of-panitumumab/2006-03-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/03/fda-approves-extended-dosing-of-aranespr-to-treat-chemotherapyinduced-anemia-everythreeweek-dosing-can-provide-added-convenience-potentially-reducing-number-of-clinic-visits-and-injections-for-anemia-treatment/2006-03-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/03/new-phase-2-data-suggest-treatment-of-anemia-with-aranespr-darbepoetin-alfa-may-provide-clinical-benefits-in-heart-failure-patients/2006-03-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/02/amgen-donates-11-million-to-the-wellness-community-as-part-of--of--breakaway-from-cancer-initiative-and-title-sponsorship-of-amgen-tour-of-california/2006-02-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/02/hundreds-of-local-residents-participate-in-breakaway-from-cancer-charity-ride-to-benefit-the-wellness-community-bruce-jenner-kicksoff-twentyfive-mile-ride-that-coincides-with-stage-six-of-amgen-tour-of-california/2006-02-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/02/investigational-therapy-denosumab-increased-bone-mineral-density-with-twiceyearly-dosing-one-year-data-published-in-new-england-journal-of-medicine/2006-02-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/02/amgen-prices-50-billion-convertible-senior-notes-company-to-purchase-approximately-30-billion-in-common-stock/2006-02-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/02/amgen-to-offer-40-billion-convertible-senior-notes-company-to-purchase-approximately-30-billion-in-common-stock/2006-02-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/02/amgen-and-biovitrum-expand-existing-license-agreement-for-innovative-treatment-of-type-2-diabetes-and-other-metabolic-disorders/2006-02-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/02/amgen-continues-manufacturing-expansion-with-additional-$1-billion-investment-in-puerto-rico/2006-02-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/01/amgen-announces-put-option-for-liquid-yield-option-notes-due-2032-and-zero-coupon-convertible-notes-due-2032/2006-01-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/01/amgens-fourth-quarter-2005-adjusted-earnings-per-share-increased-29-percent-to-75-cents-full-year-2005-adjusted-earnings-per-share-increased-33-percent-to-320/2006-01-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/01/amgen-and-genentech-sign-license-agreements-for-antibody-patents/2006-01-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/01/amgen-to-make-significant-investment-in-manufacturing-rd-and-commercial-operations-expansion/2006-01-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2006/01/amgen-announces-webcast-of-2005-fourth-quarter-and-full-year-financial-results/2006-01-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/12/amgen-to-acquire-abgenix-for-2250-per-share-provides-amgen-with-full-ownership-of-panitumumab-and-eliminates-a-denosumab-royalty/2005-12-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/12/new-phase-3-data-show-potential-benefits-of-aranespr-dosed-every-three-weeks-for-chemotherapyinduced-anemia-aranesp-treatment-achieved-and-maintained-target-hemoglobin-levels-and-reduced-incidence-of-red-blood-cell-transfusions/2005-12-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/12/interim-longterm-followup-data-show-amg-531-increases-platelets-in-patients-with-immune-thrombocytopenic-purpura-results-suggest-onceweekly-dosing-of-amg-531-results-in-sustained-platelet-response/2005-12-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/12/updated-interim-aranespr-phase-2-data-suggest-major-response-in-anemic-patients-with-myelodysplastic-syndrome-mds-patients-with-bone-marrow-disorder-also-showed-improvements-in-hemoglobin-levels-and-fatigue/2005-12-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/12/the-wellness-community-and-amgen-partner-with-professional-cyclist-george-hincapie-to-launch-breakaway-from-cancer-initiative/2005-12-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/12/amgen-announces-$5-billion-stock-repurchase-plan/2005-12-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/11/amgen-foundation-donates-500000-to-south-asia-earthquake-relief-efforts/2005-11-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/11/treatment-has-demonstrated-improvement-in-physical-function-and-kept-joint-damage-from-progressing-at-three-years/2005-11-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/11/twoyear-trial-results-of-amgen-investigational-therapy-for-bone-loss-denosumab-show-increased-bone-mineral-density-with-twiceyearly-dosing/2005-11-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/11/data-show-aranespr-darbepoetin-alfa-administered-once-monthly-maintains-hemoglobin-levels-in-chronic-kidney-disease-patients-with-anemia/2005-11-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/11/nominations-open-for-the-amgen-award-for-science-teaching-excellence-19-outstanding-teachers-will-be-recognized-in-communities-where-amgen-operates/2005-11-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/11/amgen-files-lawsuit-against-roche-for-patent-infringement/2005-11-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/11/panitumumab-significantly-improves-progression-free-survival-in-phase-3-randomized-metastatic-colorectal-cancer-study/2005-11-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/11/media-notificationwebcast-notification--amgen-and-abgenix-to-conduct-conference-call-and-webcast-regarding-panitumumab-pivotal-study-results--november-3-2005-800-am-pt/2005-11-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/11/amgen-announces-sponsorship-of-worldclass-cycling-event-company-to-join-with-the-wellness-community-to-raise-awareness-and-funds-to-help-people-fight-cancer/2005-11-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/10/european-commission-approves-kepivancetm-palifermin-for-oral-mucositis-in-cancer-patients-undergoing-blood-and-bone-marrow-transplant/2005-10-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/10/amgens-third-quarter-2005-adjusted-earnings-per-share-increased-33-percent-to-85-cents-third-quarter-2005-gaap-earnings-per-share-increased-to-77-cents-from-18-cents/2005-10-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/10/amgen-announces-webcast-of-third-quarter-financial-results/2005-10-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/09/fda-expands-neulastar-label-new-label-extends-firstcycle-protection-from-infection-to-cancer-patients-receiving-moderately-myelosuppressive-chemotherapy/2005-09-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/09/amgen-announces-fda-licensure-of-two-new-manufacturing-facilities-company-continues-to-meet-increased-demand-for-its-novel-therapeutics/2005-09-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/09/amgen-names-phyllis-piano-vice-president-corporate-communications-and-philanthropy/2005-09-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/09/amgen-announces-initiation-of-phase-3-trial-to-evaluate-the-impact-of-treating-anemia-with-darbepoetin-alfa-in-patients-with-heart-failure-to-reduce-mortality-and-hospitalization/2005-09-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/09/amgen-donates-$2-5-million-to-hurricane-katrina-relief-efforts/2005-09-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/08/amgen-names-michael-kelly-as-chief-accounting-officer/2005-08-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/08/amgen-strengthens-focus-on-oncology-pipeline-names-david-r-parkinson-to-new-role-in-research-and-development-organization/2005-08-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/08/amgen-adopts-guiding-principles-for-directtoconsumer-advertising/2005-08-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/08/abgenix-and-amgen-announce-fda-grants-panitumumab-fast-track-designation-for-metastatic-colorectal-cancer/2005-08-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/07/kepivancetm-palifermin-receives-positive-regulatory-opinion-for-approval-in-europe/2005-07-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/07/amgens-second-quarter-2005-adjusted-earnings-per-share-increased-42-percent-to-88-cents/2005-07-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/07/interim-data-suggest-major-response-with-aranespr-in-anemic-patients-with-myelodysplastic-syndromes-mds/2005-07-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/06/amgen-announces-webcast-of-second-quarter-financial-results/2005-06-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/06/fda-expands-enbrel-psoriatic-arthritis-indication----enbrel-approved-as-first-and-only-treatment-to-improve-physical-function-in-these-patients/2005-06-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/05/2005-recipients-of-amgen-award-for-science-teaching-excellence-announced-19-outstanding-science-teachers-and-their-schools-recognized-in-communities-across-us-and-puerto-rico/2005-05-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/05/amgen-names-jim-daly-senior-vice-president-north-america-commercial-operations/2005-05-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/05/further-phase-2-data-confirm-panitumumab-single-agent-antitumor-activity-in-patients-with-metastatic-colorectal-cancer/2005-05-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/05/aranesp-dosed-every-three-weeks-achieved-and-maintained-target-hemoglobin-levels-in-patients-with-chemotherapy-induced-anemia/2005-05-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/05/final-results-of-phase-3-head-to-head-study-demonstrate-aranesp-dosed-every-two-weeks-is-comparable-to-epoetin-alfa-dosed-weekly-in-cancer-patients-with-chemotherapy-induced-anemia/2005-05-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/05/large-community-based-clinical-trial-in-older-cancer-patients-suggests-benefits-of-neulasta-in-first-and-subsequent-cycles-of-chemotherapy/2005-05-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/05/amgen-submits-supplemental-biologics-license-application-for-aranesp-extended-dosing-phase-3-study-evaluated-aranesp-dosed-once-every-three-weeks-in-patients-with-chemotherapyinduced-anemia/2005-05-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/05/amgen-announces-expiration-and-results-of-its-exchange-offer-for-its-outstanding-liquid-yield-option-notes-due-2032/2005-05-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/05/amgen-announces-one-day-extension-of-its-exchange-offer-for-its-outstanding-liquid-yield-option-notes-due-2032/2005-05-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/05/amgen-announces-plans-to-webcast-selected-management-presentations/2005-05-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/04/phase-3-clinical-trial-initiated-to-evaluate-the-use-of-panitumumab-therapy-for-firstline-treatment-of-metastatic-colorectal-cancer-study-evaluates-panitumumab-administered-with-bevacizumab-and-chemotherapy/2005-04-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/04/amgens-first-quarter-2005-adjusted-earnings-per-share-increased-26-percent-to-72-cents/2005-04-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/04/landmark-trial-to-link-reduction-in-cardiovascular-risk-with-treatment-of-anemia-in-diabetics-with-chronic-kidney-disease/2005-04-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/04/multimedia-available-landmark-trial-to-link-reduction-in-cardiovascular-risk-with-treatment-of-anemia-in-diabetics-with-chronic-kidney-disease/2005-04-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/04/amgen-commences-exchange-offer-for-its-outstanding-liquid-yield-option-notes-due-2032/2005-04-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/04/amgen-announces-webcast-of-first-quarter-financial-results/2005-04-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/03/landmark-trial-will-evaluate-the-impact-of-treating-anemia-on-cardiovascular-outcomes-in-patients-with-chronic-kidney-disease-and-type-2-diabetes/2005-03-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/03/amgen-announces-results-of-its-repurchase-of-tendered-liquid-yield-option-notes-due-2032/2005-03-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/02/phase-3-study-published-in-the-journal-of-clinical-oncology-shows-first-cycle-administration-of-neulasta-significantly-lowers-incidence-of-neutropenia-with-related-fever-and-hospitalization/2005-02-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/02/amgen-announces-one-time-cash-payment-and-additional-put-right-for-liquid-yield-option-notes-due-2032/2005-02-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/02/treatment-with-enbrel-had-a-positive-effect-on-activities-of-daily-living-for-patients-with-psoriasis/2005-02-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/02/following-complete-review-of-phase-2-trial-data-amgen-confirms-decision-to-halt-gdnf-study-comprehensive-review-of-scientific-findings-patient-safety-drove-decision/2005-02-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/01/amgen-announces-put-option-notification-for-liquid-yield-option-notes-due-2032/2005-01-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/01/amgens-fourth-quarter-2004-adjusted-earnings-per-share-increased-26-percent-to-58-cents-full-year-2004-adjusted-earnings-per-share-increased-26-percent-to-240/2005-01-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/01/amgen-announces-webcast-of-2004-fourth-quarter-and-full-year-financial-results/2005-01-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/01/amgen-significantly-expands-support-of-patient-assistance-programs-financial-support-to-help-ensure-patients-have-access-to-innovative-therapies-critical-to-care/2005-01-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2005/01/amgen-donates-1-million-and-establishes-tsunami-relief-program-staff-donations-company-contributions-to-help-south-asia-victims/2005-01-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/12/fda-approves-kepivance-for-severe-oral-mucositis-in-cancer-patients-undergoing-bone-marrow-transplant-pivotal-phase-3-study-published-in-this-weeks-new-england-journal-of-medicine/2004-12-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/12/amgen-names-willard-dere-senior-vice-president-global-development/2004-12-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/12/randomized-head-to-head-trial-shows-aranesp-dosed-every-two-weeks-is-comparable-to-epoetin-alfa-dosed-once-a-week-in-breast-cancer-patients/2004-12-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/12/phase-3-study-shows-majority-of-neutropenia-with-related-fever-and-hospitalization-occurs-in-first-treatment-cycle-for-breast-cancer-patients-not-receiving-neulasta/2004-12-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/12/amgen-announces-$5-billion-stock-repurchase-plan/2004-12-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/12/fda-grants-fast-track-designation-for-amgens-amg-531-and-amg-706-experimental-therapies-to-potentially-treat-lifethreatening-conditions/2004-12-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/11/nominations-open-for-the-amgen-award-for-science-teaching-excellence-19-outstanding-teachers-will-be-recognized-in-communities-where-amgen-operates/2004-11-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/11/nominations-open-for-the-amgen-award-for-science-teaching-excellence/2004-11-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/11/published-head-to-head-data-show-aranesp-dosed-every-two-weeks-is-comparable-to-epoetin-alfa-dosed-once-a-week/2004-11-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/11/amgen-announces-offer-of-$2-billion-in-two-series-of-senior-notes/2004-11-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/11/amgen-announces-the-formation-of-amgen-ventures-venture-capital-fund-designed-to-provide-resources-to-help-advance-earlystage-biotechnology-companies-and-human-therapeutics/2004-11-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/11/amgen-launches-landmark-trial-to-evaluate-the-impact-of-treating-anemia-on-cardiovascular-risks-in-patients-with-chronic-kidney-disease-and-type-2-diabetes/2004-11-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/11/interim-phase-2-data-suggest-activity-of-panitumumab-with-chemotherapy-in-first-line-treatment-of-metastatic-colorectal-cancer/2004-11-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/10/european-commission-approves-innovative-first-in-class-treatment-for-a-serious-complication-of-chronic-kidney-disease/2004-10-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/10/amgens-third-quarter-2004-adjusted-earnings-per-share-increased-21-percent-to-64-cents/2004-10-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/10/new-two-year-data-show-that-most-rheumatoid-arthritis-patients-treated-with-enbrel-plus-methotrexate-had-no-progression-of-joint-damage/2004-10-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/10/court-rules-in-amgens-favor-in-tkt-litigation-affirms-validity-of-epo-patents/2004-10-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/10/amgen-names-rolf-hoffmann-senior-vice-president-european-operations/2004-10-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/10/amgen-announces-webcast-of-third-quarter-financial-results/2004-10-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/10/amgen-investigational-therapy-for-bone-loss-amg-162-increased-bone-mineral-density-with-twice-yearly-injection/2004-10-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/09/fda-approves-enbrel-to-induce-major-clinical-response-in-patients-with-rheumatoid-arthritis-additional-data-demonstrates-increased-levels-of-sustained-disease-control/2004-09-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/09/fda-approves-new-and-easy-way-to-take-enbrel-benefits-of-enbrel-delivered-in-convenient-onceweekly-50-mgml-prefilled-syringe/2004-09-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/09/amgen-announces-plans-to-webcast-selected-management-presentations/2004-09-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/09/aranesp-approved-for-extended-dosing-by-european-commission/2004-09-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/09/amgen-names-arvind-sood-vice-president-investor-relations/2004-09-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/08/amgen-completes-acquisition-of-tularik-acquisition-enhances-amgens-strong-research-organization-and-establishes-amgen-in-the-san-francisco-bay-area/2004-08-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/08/first-patients-dosed-with-amgens-amg-162-in-phase-3-studies-for-postmenopausal-osteoporosis-and-treatmentinduced-bone-loss/2004-08-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/08/aranesp-receives-positive-regulatory-opinion-for-extended-dosing-in-europe/2004-08-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/07/mimpara----cinacalcet-hcl----receives-positive-regulatory-opinion-for-approval-in-europe/2004-07-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/07/lifestyle-coaching-program-launched-today-helps-people-with-rheumatoid-arthritis-remain-active/2004-07-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/07/amgens-second-quarter-2004-total-product-sales-adjusted-earnings-and-gaap-earnings-per-share-increased-27-percent/2004-07-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/07/amgen-names-brian-kotzin-vice-president-inflammation-clinical-development-and-willard-dere-vice-president-general-medicine/2004-07-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/07/amgen-announces-webcast-of-second-quarter-financial-results/2004-07-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/07/amgen-names-joshua-ofman-vice-president-reimbursement-and-payment-policy/2004-07-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/06/amgens-phase-2-study-of-gdnf-for-advanced-parkinsons-disease-fails-to-meet-primary-endpoint-six-months-of-treatment-showed-biological-effect-but-no-clinical-improvement/2004-06-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/06/phase-3-study-shows-first-cycle-administration-of-neulasta-significantly-lowers-incidence-of-infection-and-hospitalization/2004-06-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/06/amgen-submits-biologics-license-application-for-fda-approval-of-palifermin/2004-06-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/06/new-two-year-data-demonstrate-that-enbrel-therapy-allowed-significantly-more-rheumatoid-arthritis-patients-to-achieve-clinical-remission/2004-06-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/06/head-to-head-studies-show-aranesp-dosed-every-two-weeks-is-comparable-to-epoetin-alfa-dosed-once-a-week/2004-06-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/06/study-results-demonstrate-aranesp-dosed-once-every-three-weeks-achieves-treatment-goals-in-managing-anemia-in-cancer-patients-receiving-chemotherapy/2004-06-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/06/study-results-demonstrate-the-activity-of-aranesp-in-treating-anemia-in-cancer-patients-not-receiving-chemotherapy/2004-06-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/06/interim-phase-2-data-show-panitumumab-has-singleagent-antitumor-activity-in-metastatic-colorectal-cancer-response-appears-independent-of-prior-chemotherapy-regimen/2004-06-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/05/catwalk-beauty-vendela-to-help-educate-public-about-effects-of-psoriasis-through-making-connections-health-education-campaign/2004-05-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/04/fda-approves-enbrel-to-treat-psoriasis-new-convenient-treatment-provides-rapid-and-significant-relief-of-symptoms/2004-04-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/04/2004-cambridge-boston-recipients-of-amgen-award-for-science-teaching-excellence-announced/2004-04-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/04/2004-rhode-island-recipients-of-amgen-award-for-science-teaching-excellence-announced/2004-04-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/04/amgens-first-quarter-2004-adjusted-earnings-per-share-increased-36-percent-to-57-cents/2004-04-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/04/2004-puerto-rico-recipients-of-amgen-award-for-science-teaching-excellence-announced/2004-04-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/04/2004-washington-recipients-of-amgen-award-for-science-teaching-excellence-announced/2004-04-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/04/2004-california-recipients-of-amgen-award-for-science-teaching-excellence-announced/2004-04-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/04/2004-colorado-recipients-of-amgen-award-for-science-teaching-excellence-announced/2004-04-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/04/2004-kentucky-recipients-of-amgen-award-for-science-teaching-excellence-announced/2004-04-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/04/amgen-announces-webcast-of-first-quarter-financial-results/2004-04-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/04/immunomedics-regains-north-american-development-rights-from-amgen-for-epratuzumab/2004-04-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/04/sensipar-pivotal-studies-in-over-700-patients-published-in-new-england-journal-of-medicine/2004-04-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/03/amgen-names-rodger-currie-vice-president-government-affairs/2004-03-30monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/03/amgen-to-acquire-tularik-for-$1-3-billion/2004-03-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/03/amgens-first-research-and-development-day-highlighted-24-of-the-approximately-40-programs-in-its-pipeline/2004-03-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/03/frank-herringer-nominated-for-amgen-board-of-directors/2004-03-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/03/leonard-schaeffer-joins-amgens-board-of-directors/2004-03-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/03/fda-approves-innovative-firstinclass-treatment-for-a-serious-complication-of-chronic-kidney-disease/2004-03-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/02/amgen-opens-state-of-the-art-biotechnology-research-campus/2004-02-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/02/amgen-announces-webcast-of-rd-day-with-the-investment-community/2004-02-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/02/new-phase-3-enbrel-data-show-psoriasis-patients-achieved-a-therapeutic-response-from-step-down-dosing-regimen/2004-02-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/01/amgens-fourth-quarter-2003-adjusted-earnings-per-share-increased-31-percent-to-46-cents-full-year-2003-adjusted-earnings-per-share-increased-37-percent-to-190/2004-01-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/01/amgen-announces-webcast-of-fourth-quarter-and-full-year-2003-financial-results/2004-01-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/01/amgen-names-david-j-scott-senior-vice-president-general-counsel-and-secretary/2004-01-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/01/amgen-announces-award-for-science-teaching-excellence-in-rhode-island/2004-01-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/01/amgen-announces-award-for-science-teaching-excellence-in-colorado/2004-01-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/01/amgen-announces-award-for-science-teaching-excellence-in-california/2004-01-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/01/amgen-announces-award-for-science-teaching-excellence/2004-01-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/01/amgen-announces-award-for-science-teaching-excellence/2004-01-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/01/amgen-announces-award-for-science-teaching-excellence/2004-01-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2004/01/amgen-announces-award-for-science-teaching-excellence-in-puerto-rico/2004-01-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/12/amgen-named-one-of-fortune-magazines-100-best-companies-to-work-for/2003-12-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/12/amgen-forecasts-strong-2004-financial-performance/2003-12-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/12/amgen-names-david-beier-senior-vice-president-global-government-affairs/2003-12-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/12/phase-3-data-show-palifermin-improves-patient-reported-outcomes-in-cancer-patients-and-helps-reduce-hospitalizations-and-healthcare-resources/2003-12-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/12/analysis-of-headtohead-studies-shows-that-aranespr-dosed-every-two-weeks-offers-similar-results-with-less-frequent-administration-compared-to-epoetin-alfa/2003-12-07monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/12/new-data-suggest-aranespr-benefits-patients-suffering-from-anemia-of-cancer-who-are-not-receiving-chemotherapy/2003-12-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/12/amgen-announces-webcast-of-conference-call-to-provide-financial-guidance-for-2004/2003-12-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/11/aranespr-administered-once-monthly-maintains-hemoglobin-levels-in-patients-with-chronic-kidney-disease/2003-11-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/11/cinacalcet-hcl-phase-3-results-demonstrate-improvement-in-the-management-of-secondary-hyperparathyroidism-in-patients-with-chronic-kidney-disease/2003-11-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/11/amgen-announces-plans-for-epratuzumab/2003-11-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/10/longterm-data-support-sustained-efficacy-tolerability-and-increased-vitality-for-psoriatic-arthritis-patients-treated-with-enbrel-and-landmark-phase-3-data-show-ankylosing-spondylitis-patients-experienced-partial-clinical-remission-improved-pain-relief/2003-10-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/10/new-data-show-many-rheumatoid-arthritis-patients-treated-with-enbrel-plus-methotrexate-have-experienced-clinical-remission-and-most-had-no-progression-of-joint-damage/2003-10-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/10/science-recognizes-amgen-as-a-top-employer-in-annual-survey/2003-10-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/10/amgens-third-quarter-2003-adjusted-earnings-per-share-increases-56-to-53-cents/2003-10-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/10/fda-approves-enbrel-for-once-weekly-dosing/2003-10-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/10/amgen-names-h-christian-fibiger-phd-and-paul-g-pearson-phd-as-vice-presidents-to-lead-research-efforts/2003-10-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/10/abgenix-and-amgen-clarify-responsibilities-for-abx-egf/2003-10-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/10/amgen-announces-webcast-of-third-quarter-2003-financial-results/2003-10-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/09/amgen-and-biovitrum-sign-license-agreement-for-innovative-treatment-of-type-2-diabetes-and-other-metabolic-disorders/2003-09-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/09/amgen-submitted-new-drug-applicatioin-for-cinacalcet-hci/2003-09-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/09/amgen-foundation-gives-$8-million-in-grants-in-2002/2003-09-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/08/amgen-and-genentech-settle-patent-dispute/2003-08-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/08/fda-approves-enbrel-as-first-therapy-to-inhibit-bone-and-joint-damage-in-psoriatic-arthritis-patients/2003-08-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/07/fda-approves-enbrelr-as-treatment-to-improve-physical-function-in-rheumatoid-arthritis-patients/2003-07-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/07/enbrel-is-first-biologic-to-receive-fda-approval-for-the--treatment-of-ankylosing-spondylitis/2003-07-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/07/ten-thousand-patients-enrolled-in-landmark-rheumatoid-arthritis-study-program/2003-07-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/07/amgen-names-dr-willard-dere-vice-president-global-inflammation-clinical-development/2003-07-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/07/enbrel-is-first-anti-tnf-therapy-submitted-to-the-fda-for-approval-to-treat-psoriasis/2003-07-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/07/amgen-announces-webcast-of-second-quarter-2003/2003-07-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/06/enbrel-is-first-biologic-recommended-by-fda-panel-for-approval-to-treat-ankylosing-spondylitis/2003-06-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/06/enbrel-combination-therapy-inhibited-progression-of-joint-damage-and-offered-significant-rheumatoid-arthritis-symptom-relief-in-new-clinical-study/2003-06-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/06/enbrel-provided-rapid-and-significant-relief-for-psoriasis-patients-in-second-pivotal-study/2003-06-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/06/enbrel-rapidly-and-significantly-improved-back-pain-mobility-and-physical-function-in-patients-with-ankylosing-spondylitis/2003-06-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/06/in-a-new-clinical-study-enbrel-taken-once-weekly-significantly-reduced-pain-and-inflammation-and-improved-function-in-rheumatoid-arthritis-patients/2003-06-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/06/new-data-highlight-aranesp-efficacy-in-anemic-patients-with-lymphoid-cancer/2003-06-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/06/new-study-demonstrates-combination-therapy-with-enbrel-inhibited-progression-of-joint-damage-and-offered-significant-symptom-relief-for-rheumatoid-arthritis-patients/2003-06-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/06/amgen-announces-first-annual-recipient-of-the-amgen-prize-for-therapeutic-advances-in-nephrology/2003-06-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/06/new-data-suggest-risk-of-infection-doubles-with-reduced-neupogen-administration/2003-06-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/06/aranesp-dosed-once-every-two-weeks-increases-hemoglobin-levels-improves-fatigue-and-reduces-need-for-transfusions-in-patients-with-chemotherapyinduced-anemia/2003-06-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/06/phase-3-data-suggest-palifermin-significantly-reduces-the-duration-and-incidence-of-oral-mucositis-in-cancer-patients/2003-06-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/05/amgen-launches-the-amgen-oncology-institute-to-support-cancer-education/2003-05-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/05/interim-phase-2-data-demonstrate-single-agent-antitumor-activity-with-abx-egf-in-advanced-colorectal-cancer/2003-05-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/05/deborah-norville-launches-national-hope-relay-in-celebration-of-people-leading-active-lives-despite-their-rheumatoid-arthritis/2003-05-28monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/05/amgen-appoints-industry-veteran-dr--david-r--parkinson-to-head-oncology-clinical-development/2003-05-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/05/2003-california-recipients-of-amgen-award-for-science-teaching-excellence-announced/2003-05-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/05/2003-colorado-recipients-of-amgen-award-for-science-teaching-excellence-announced/2003-05-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/05/2003-jefferson-county-recipients-of-amgen-award-for-science-teaching-excellence-announced/2003-05-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/05/2003-puerto-rico-recipients-of-amgen-award-for-science-teaching-excellence-announced/2003-05-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/05/2003-rhode-island-recipients-of-amgen-award-for-science-teaching-excellence-announced/2003-05-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/05/2003-seattle-area-recipients-of-amgen-award-for-science-teaching-excellence-announced/2003-05-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/04/amgen-announces-webcast-of-first-quarter-2003-financial-results/2003-04-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/03/amgen-announces-800-million-investment-in-juncos-puerto-rico-for-biotech-manufacturing-center/2003-03-20monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/03/rob-lowe-launches-town-meetings-to-help-cancer-patients-and-their-loved-ones-understand-chemotherapy-and-its-side-effects/2003-03-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/02/amgen-provides-business-overview-through-2005/2003-02-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/02/amgen-announces-webcast-of-business-review-meeting/2003-02-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/01/jj-ordered-to-pay-amgens-costs-and-attorneys-fees-in-recent-arbitration/2003-01-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/01/amgen-announces-award-for-science-teaching-excellence/2003-01-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/01/amgen-announces-award-for-science-teaching-excellence-in-california/2003-01-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/01/amgen-announces-award-for-science-teaching-excellence-in-colorado/2003-01-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/01/amgen-announces-award-for-science-teaching-excellence-in-king-and-snohomish-counties/2003-01-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/01/amgen-announces-award-for-science-teaching-excellence-in-rhode-island/2003-01-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/01/amgen-and-immunomedics-announce-emphasis-on-development-of-amg-412-epratuzumab-as-combination-therapy-while-closing-single-agent-trial/2003-01-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/01/amgen-announces-positive-results-of-phase-3-study-for-rhu-kgf/2003-01-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/01/on-an-adjusted-basis-amgen-reports-fourth-quarter-earnings-per-share-increase-17-percent-to-35-cents-full-year-2002-increase-18-percent-to-139/2003-01-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/01/amgen-announces-positive-results-of-phase-3-enbrel-study-in-psoriasis/2003-01-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/01/amgen-announces-webcast-of-fourth-quarter-and-full-year-2002-financial-results/2003-01-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/01/federal-appeals-court-affirms-tkt-infringement-remands-certain-validity-issues-to-lower-court/2003-01-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2003/01/epogen---important-prescribing-information/2003-01-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/12/court-dismisses-amgen-reimbursement-challenge/2002-12-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/12/amgen-submits-data-to-fda-supporting-once-weekly-dosing-of-enbrel/2002-12-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/12/fda-approves-enbrel-manufacturing-facility-supply-for-patients-dramatically-increases/2002-12-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/12/data-from-study-shows-aranesp-dosed-every-other-week-more-cost-effective-than-epoetin-alfa-for-treating-anemia-in-chemotherapy-patients/2002-12-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/12/amgen-announces-results-of-phase-3-study-of-enbrel-dosed-once-weekly/2002-12-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/12/amgen-announces-webcast-of-conference-call-to-provide-financial-guidance-for-2003/2002-12-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/12/enbrel-offered-to-additional-40000-rheumatoid-arthritis-juvenile-rheumatoid-arthritis-and-psoriatic-arthritis-patients/2002-12-02monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/11/amgen-files-suit-seeking-relief-from-reimbursement-ruling/2002-11-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/11/serono-and-amgen-sign-license-agreement-for-multiple-sclerosis-product/2002-11-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/11/amgen-business-review-meeting-resheduled-to-february-25-2003/2002-11-05monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/11/first-in-class-oral-calcimimetic-shown-to-reduce-parathyroid-hormone-levels-in-chronic-kidney-disease/2002-11-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/11/first-in-class-oral-calcimimetic-shown-to-reduce-parathyroid-hormone-levels-in-chronic-kidney-disease/2002-11-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/11/new-data-on-aranespr-dosed-every-other-week-in-anemic-chronic-kidney-disease-patients-presented-at-35th-annual-meeting-of-the-american-society-of-nephrology/2002-11-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/10/amgen-comment-on-new-opps-rule/2002-10-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/10/enbrelr-only-tnf-receptor-with-five-years-sustained-data-in-treatment-of-rheumatoid-arthritis/2002-10-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/10/enbrelr-is-first-therapy-shown-to-inhibit-bone-and-joint-damage-in-psoriatic-arthritis-patients/2002-10-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/10/amgen-announces-positive-study-results-of-kineretr--in-rheumatoid-arthritis-disease-progression-and-in-the-treatment-of-juvenile-rheumatoid-arthritis/2002-10-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/10/enbrelsuprsup-first-therapy-submitted-to-fda-showing-inhibition-of-bone-and-joint-damage-in-psoriatic-arthritis-patients/2002-10-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/10/amgens-third-quarter-2002-adjusted-earnings-per-share-increase-13-to-34-cents/2002-10-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/10/amgen-files-with-fda-for-use-of-kineretsuprsup-to-inhibit-bone-and-joint-damage-due-to-rheumatoid-arthritis/2002-10-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/10/amgen-wins-arbitration-and-awarded-150-million-against-johnson--johnson/2002-10-18monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/10/amgen-and-wyeth-pharmaceuticals-announce-initiation-of-landmark-study-in-rheumatoid-arthritis/2002-10-17monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/10/amgen-announces-webcast-of-third-quarter-2002-financial-results/2002-10-09monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/09/amgen-submits-data-to-fda-supporting-use-of-enbrel-to-improve-physical-function-in-rheumatoid-arthritis-patients/2002-09-26monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/08/rob-lowe-introduces-one-to-one-support-network-for-new-cancer-patients/2002-08-29monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/08/amgen-announces-filing-with-fda-for-licensure-of-enbrel-production-facility-in-rhode-island/2002-08-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/07/second-quarter-2002-earnings-per-share-increase-27-percent-to-38-cents/2002-07-24monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/07/fda-approves-amgens-aranesp-for-anemia-associated-with-chemotherapy/2002-07-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/07/amgen-announces-webcast-of-second-quarter-2002-financial-results/2002-07-19monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/07/amgen-completes-acquisition-of-immunex/2002-07-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/06/amgen-announces-$2-billion-stock-repurchase-plan/2002-06-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/06/amgen-receives-cpmp-recommendation-for-european-union-marketing-approval-of-neulasta-for-the-reduction-of-chemotherapy---induced-neutropenia/2002-06-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/06/amgen-receives-cpmp-positive-recommendation-for-european-union-regulatory-approval-of-aranesprn-oncology/2002-06-03monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/05/amgen-announces-its-registration-statement-on-form-s-3-has-been-declared-effective/2002-05-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/05/amgen-files-registration-statement-in-connection-with-its-zero-coupon-convertible-notes/2002-05-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/05/aranesp-studies-explore-potential-of-new-anemia-treatment-paradigms/2002-05-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/05/amgen-stockholders-approve-issuance-of-shares-in-connection-with-immunex-acquisition/2002-05-16monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/05/hassan-dayem-will-join-amgen-as-senior-vice-president-and-chief-information-officer/2002-05-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/05/important-drug-warning-counterfeiting-of-epogenr/2002-05-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/05/amgen-to-acquire-filgrastim-and-pegfilgrastim-in-europe-from-roche/2002-05-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/04/amgen-reports-first-quarter-2002-earnings-per-share-increased-14-percent-to-32-cents/2002-04-25monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/04/2002-recipients-of-amgen-award-for-science-teaching-excellence-announced-california/2002-04-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/04/2002-recipients-of-amgen-award-for-science-teaching-excellence-announced-jefferson-county-kentucky/2002-04-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/04/2002-recipients-of-amgen-award-for-science-teaching-excellence-announced-boulder-county-colorado/2002-04-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/04/rob-lowe-launches-awareness-campaign-about-one-of-the-most-dangerous-and-unrecognized-side-effects-of-chemotherapy----infections/2002-04-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/04/amgen-announces-webcast-of-first-quarter-2002-financial-results/2002-04-12monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/03/amgen-signs-multiyear-agreement-with-us-oncology-for-aranesp-neulasta-and-neupogen/2002-03-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/03/amgen-signs-multiyear-agreement-with-international-oncology-network-for-aranesp-neulasta-and-neupogen/2002-03-14monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/03/european-commission-approves-amgens-kineret-for-the-treatment-of-rheumatoid-arthritis-first-interleukin1-receptor-antagonist-represents-new-way-to-treat-ra/2002-03-13monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/02/multimedia-available-whats-your-aq--anemia-quotient/2002-02-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/02/multimedia-available-actor-danny-glover-joins-anemia-lifeline-to-help-millions-of-americans-who-suffer-from-anemia-associated-with-serious-diseases/2002-02-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/02/actor-danny-glover-joins-anemia-lifelinetm-to-help-millions-of-americans-who-suffer-from-anemia-associated-with-serious-diseases/2002-02-27monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/02/amgen-to-receive-$2-5-billion-from-offering-of-zero-coupon-senior-convertible-notes/2002-02-22monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/02/amgen-to-raise-$2-5-billion-from-offering-of-zero-coupon-senior-convertible-notes/2002-02-21monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/02/amgen-and-immunex-receive-request-for-additional-information-from-the-federal-trade-commission/2002-02-06monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/02/the-united-states-pharmacopeia-accepts-amgens-aranesp-for-treatment-of-chemotherapyassociated-anemia/2002-02-04monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/02/update-fda-approves-amgens-neulasta-for-serious-and-frequent-chemotherapy-side-effect/2002-02-01monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/01/multimedia-available-fda-approves-amgens-neulasta-for-serious--frequent-chemotherapy-side-effect/2002-01-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/01/fda-approves-amgens-neulasta-for-serious-and-frequent-chemotherapy-side-effect/2002-01-31monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/01/amgen-reports-fourth-quarter-and-full-year-2001-financial-results-in-line-with-guidance/2002-01-23monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/01/amgen-announces-webcast-of-fourth-quarter-and-full-year-2001-financial-results/2002-01-15monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/01/amgen-announces-award-for-science-teaching-excellence-first-year-focusing-on-science-teaching/2002-01-11monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/01/amgen-appoints-beth-seidenberg-as-senior-vice-president----development/2002-01-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/01/amgen-announces-award-for-science-teaching-excellence-in-california-first-year-focusing-on-science-teaching-a-statewide-call-for-nominations/2002-01-10monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/01/frank-biondi-joins-amgens-board-of-directors/2002-01-08monthly ://disabled.local/en/www-amgen-com/media/news-releases/2002/01/patricia-sueltz-elected-to-amgens-board-of-directors/2002-01-08monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/12/amgen-earns-best-place-to-work-for-lgbtq-equality-distinction/2017-12-18monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/11/amgen-chief-compliance-officer-cynthia-patton-named-to-black-enterprise-most-powerful/2017-11-30monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/11/amgens-operations-team-honored-with-environmental-sustainability-achievement/2017-11-14monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/10/kari-stefansson-honored-with-prestigious-award-for-significant-contributions/2017-10-18monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/10/amgen-foundation-awards-khan-academy-$3-million-to-support-development/2017-10-11monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/09/amgen-again-named-to-dow-jones-sustainability-indices/2017-09-26monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/09/join-team-amgen-and-light-the-night-this-fall-for-blood-cancer-patients/2017-09-18monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/08/amgen-foundation-commits-250000-dollars-to-disaster-relief-efforts/2017-08-29monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/07/new-study-reveals-why-some-t-cells-fail-to-fight-cancer/2017-07-25monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/07/the-shape-of-drugs-to-come/2017-07-19monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/07/amgen-named-a-2017-biospace-ideal-employer/2017-07-17monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/06/amgen-ceo-bob-bradway-gives-ucla-commencement-speech/2017-06-28monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/06/listen-to-nprs-coverage-of-the-amgen-biotech-experience/2017-06-27monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/06/amgen-wins-2017-green-chemistry-challenge-award-from-the-us-environmental-protection-agency/2017-06-13monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/05/amgen-tour-of-california-2017/2017-05-11monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/05/join-amgen-in-recognizing-melanoma-awareness-month/2017-05-01monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/03/amgen-joins-the-imf-to-raise-awareness-during-myeloma-action-month/2017-03-21monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/03/join-amgens-migraine-symposia-at-aan-this-april/2017-03-16monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/03/march-is-colorectal-cancer-awareness-month--do-you-know-about-biomarkers/2017-03-01monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/02/support-rare-disease-day-2017-with-amgen/2017-02-28monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/02/amgen-inventors-honored/2017-02-06monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/01/amgen-supports-world-cancer-day/2017-01-30monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2017/01/who-builds-la---girls/2017-01-27monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/12/remembering-bill-bowes---visionary-investor-and-philanthropist/2016-12-31monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/12/making-an-impact-around-the-globe-amgen-china-supports-local-students/2016-12-08monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/11/amgen-premieres-we-are-video-emphasizing-commitment-to-migraine-prevention/2016-11-03monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/10/10-years-in-amgen-scholars-program-continues-its-commitment-to-student-scientists/2016-10-31monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/10/amgen-speaks-out-against-ca-prop-61/2016-10-25monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/10/ceo-robert-bradway-accepts-grace-award/2016-10-21monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/10/making-an-impact-around-the-globe-rhode-island/2016-10-13monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/10/djsi-recognizes-amgen-to-be-among-top-performers-in-the-biotechnology-industry-for-a-third-year/2016-10-07monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/10/amgen-is-committed-to-raising-awareness-about-the-risk-of-infection/2016-10-05monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/10/scientist-awarded-for-research-to-reveal-mysteries-of-cells-that-make-amgen-medicines/2016-10-03monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/09/making-an-impact-around-the-globe-amgen-france/2016-09-12monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/09/amgen-recognizes-cancer-awareness-month/2016-09-08monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/08/amgen-launches-commercial-office-in-hong-kong/2016-08-11monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/08/making-an-impact-around-the-globe-hats-off-to-san-francisco/2016-08-05monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/06/making-an-impact-around-the-globe-a-garden-makeover-for-molly/2016-06-28monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/06/making-an-impact-around-the-globe-czech-republic-staff/2016-06-15monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/06/amgen-korea-celebrates-new-office-opening/2016-06-09monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/05/amgen-opens-new-affiliate-in-taiwan/2016-05-31monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/05/amgen-senior-leaders-advance-discussion-on-cancer-at-2016-world-medical-innovation-forum/2016-05-23monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/05/cr-magazine-names-amgen-to-list-of-100-best-corporate-citizens/2016-05-19monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/05/amgen-thanks-oncology-nurses-there-every-step-of-the-way/2016-05-19monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/05/amgen-thanks-collaborators-in-cancer-care/2016-05-18monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/05/amgen-tour-of-california-2016/2016-05-13monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/05/amgen-and-joe-montana-launch-breakaway-from-heart-disease-to-make-heart-health-a-priority/2016-05-11monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/05/making-a-world-of-difference/2016-05-04monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/05/join-amgen-in-recognizing-melanoma-awareness-month/2016-05-03monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/02/raise-your-voice-support-rare-disease-day-2016-with-amgen/2016-02-27monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/02/join-amgen-in-supporting-world-cancer-day-2016/2016-02-03monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2016/02/thanks-for-an-incredible-2015/2016-02-02monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/10/amgen-foundation-supports-khan-academy-to-grow-biology-resources-for-students/2015-10-05monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/10/amgen-again-places-on-djsi-world-index/2015-10-01monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/09/a-message-from-the-heart-on-fh-awareness-day/2015-09-24monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/08/amgen-moves-up-in-newsweek-green-rankings/2015-08-19monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/07/the-shape-of-drugs-to-come/2015-07-29monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/07/repatha-evolocumab-now-approved-in-the-eu/2015-07-21monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/06/ten-inspiring-breakaway-from-cancer-champions-recognized-at-the-2015-amgen-tour-of-california/2015-06-23monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/06/amgen-foundation-supports-new-mit-online-course-on-the-manufacturing-of-biologics/2015-06-18monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/06/amgen-partners-with-mit-and-woodrow-wilson-foundation-to-support-new-teacher-program/2015-06-16monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/05/amgen-at-asco-2015/2015-05-28monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/05/amgens-35th-a-day-of-recognition-for-amgens-ace-and-second-ceo/2015-05-22monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/05/amgen-ranked-best-healthcare-company-to-work-for-by-business-insider/2015-05-07monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/05/chairman-and-ceo-robert-bradway-speaks-at-world-medical-innovation-forum-in-boston/2015-05-07monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/04/fda-approves-corlanor-ivabradine/2015-04-15monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/04/amgen-celebrates-35-years/2015-04-08monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/03/shades-of-blue---amgen-recognizes-colorectal-cancer-awareness-month/2015-03-27monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/03/amgen-at-acc-15/2015-03-09monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/02/the-american-heart-association-recognizes-amgen/2015-02-11monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2015/01/new-data-published-in-mayo-clinic-proceedings/2015-01-07monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2014/11/amgen-opens-asia-research-and-development-center-in-shanghai/2014-11-17monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2014/11/amgen-at-aha-scientific-sessions-2014/2014-11-12monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2014/11/amgen-scholars-program-expands-globally/2014-11-12monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2014/10/watch-pbs-segment-on-biologic-and-biosimilar-medications/2014-10-27monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2014/09/september-is-national-cholesterol-education-month/2014-09-19monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2014/08/now-available-amgen-scholars-program-2013-annual-report/2014-08-06monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2014/07/learn-about-amgens-involvement-in-brazils-science-without-borders-program/2014-07-10monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2014/07/ongoing-philanthropy-video-series/2014-07-09monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2014/05/amgen-at-asco-2014/2014-05-27monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2014/03/amgen-at-acc-14/2014-03-24monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2014/03/amgens-commitment-to-science-education-advances-future-of-innovation/2014-03-06monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2014/02/cdc-offers-important-tips-and-resources-to-help-cancer-patients/2014-02-11monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/11/amgen-at-aha-scientific-sessions-2013/2013-11-19monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/10/emmy-winning-makeup-artist-jan-ping-partners-with-amgen/2013-10-18monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/10/the-human-genome-project-wasnt-overhyped/2013-10-04monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/10/amgen-astellas-biopharma-appoints-leadership-team-begins-operations/2013-10-02monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/09/amgen-and-betta-pharma-announce-approval-of-joint-venture-in-china/2013-09-26monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/09/amgen-scholars-from-21-countries-across-europe-enjoy-scientific-and-cultural-exchange/2013-09-23monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/09/amgen-at-2013-european-cancer-congress/2013-09-12monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/09/robert-bradway-named-a-top-100-ceo-leader-in-stem/2013-09-04monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/08/we-owe-it-to-patients-to-provide-a-reliable-supply-of-medicines/2013-08-14monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/08/2012-amgen-foundation-contributions-report-and-amgen-scholars-program-annual-report-now-available/2013-08-07monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/06/nhra-world-champion-jack-beckman-and-amgen-team-up-for-chemotherapy-myths-or-facts-campaign/2013-06-11monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/05/introducing-biotechnology-by-amgen/2013-05-31monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/05/amgen-at-asco-2013/2013-05-15monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/05/amgen-tour-of-california-2013/2013-05-10monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/04/a-letter-from-amgens-chairman-and-chief-executive-officer/2013-04-04monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/03/amgen-brings-biotechnology-to-classrooms/2013-03-01monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/02/amgen-supports-rare-disease-day/2013-02-28monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/02/amgen-and-dr--john-petricciani-explain-why-precise-manufacturing-of-biological-medicines-matters/2013-02-07monthly ://disabled.local/en/www-amgen-com/www-amgen-com/media/featured-news/2013/02/amgen-outlines-its-long-term-strategy-to-analysts-and-investors/2013-02-07monthly